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Rb
p53The oncogenic potential of papillomaviruses (PVs) has been appreciated since the 1930s yet the mechanisms
of virally-mediated cellular transformation are still being revealed. Reasons for this include: a) the oncopro-
teins are multifunctional, b) there is an ever-growing list of cellular interacting proteins, c) more than one
cellular protein may bind to a given region of the oncoprotein, and d) there is only limited information on
the proteins encoded by the corresponding non-oncogenic PVs. The perspective of this review will be to con-
trast the activities of the viral E6 and E7 proteins encoded by the oncogenic human PVs (termed high-risk
HPVs) to those encoded by their non-oncogenic counterparts (termed low-risk HPVs) in an attempt to sort
out viral life cycle-related functions from oncogenic functions. The review will emphasize lessons learned
from the cell culture studies of the HPVs causing mucosal/genital tract cancers.
© 2011 Elsevier Inc. All rights reserved.Introduction
Papillomaviruses cause benign hyperproliferative disease and ma-
lignances (zur Hausen, 2009). The purpose of this review is to discuss
various aspects of cellular transformation mediated by human papil-
lomaviruses (HPVs). In the case of polyomaviruses, e.g., SV40 and
polyoma virus, the transforming functions of the viral proteins are
only revealed when the replication functions of those proteins are
limited, either by expressing the genome in a non-permissive cell
where the viral genome cannot replicate (Murakami et al., 1986;
Watkins and Dulbecco, 1967) or by expression of the genome in a
permissive cell where the origin of replication has been mutated
(Gluzman, 1981). In the case of the HPVs, transformation and replica-
tion are again mutually exclusive, but the infected host cell is the
same so it is less easy to separate functions speciﬁc to the life cycle
of the virus from those critical to cellular transformation.
All HPVs are presumed to infect the basal cells through a microab-
rasion. In the basal cells the viral genome is maintained extrachromo-
somally at 50–100 copies per cell and no viral structural proteins are
produced; this phase is referred to as the non-productive phase. Bothlogy, Fred Hutchinson Cancer
Seattle, WA 98109-1024, USA.
rights reserved.the low level expression and genome copy number are due, at least in
part, to the presence in undifferentiated cells of cellular proteins which
negatively regulate expression of genes from the viral genome and
may compete for binding to the viral origin of replication (Ai et al.,
2000; Ai et al., 1999; Narahari et al., 2006; O'Connor et al., 2000).
Viral DNA ampliﬁcation and virion production (the productive phase
of the viral life cycle) occur in the differentiated compartment. These
differentiated cells would normally have exited the cell cycle and
would, therefore, not support the productive phase of the virus life
cycle. Thus all HPVs have to uncouple the normal proliferation:differ-
entiation switch to maintain or create an environment compatible
with viral DNA ampliﬁcation within the differentiated compartment.
One could imagine that this uncoupling would give all the HPVs the
potential to cause cancer yet only a subset of HPVs is oncogenic. The
perspective of this reviewwill be, wherever possible, to distinguish on-
cogenic functions from life cycle functions by comparing activities of
proteins encoded by HPVs associated with cancer to activities of pro-
teins encoded by HPVs associated only with benign disease.
There has been a ﬂurry of excellent reviews recently of the human
papillomaviruses and their gene products (Ghittoni et al., 2010;
Howie et al., 2009; McLaughlin-Drubin and Munger, 2009; Moody and
Laimins, 2010; Pim and Banks, 2010; Wise-Draper and Wells, 2008).
This reviewwill emphasize lessons learned from the cell culture studies
of the human alpha-PV oncoproteins (E6, and E7) each in contrast to
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cussion of the human beta-PVE6 and E7 proteins and of theHPV E5 pro-
tein. The human alpha-PVs are those infecting the mucosa/genital
epithelium and causing lower genital tract and head and neck disease;
the human beta-PVs infect cutaneous tissue and are associated with
non-melanoma skin cancer (de Villiers et al., 2004). Topics will include
regulation of cell cycle and differentiation; apoptosis, senescence and
autophagy; genomic instability; and metabolism. Although this review
will emphasize results of experiments using the reductionist approach,
i.e. analyzing the activity of a single protein, it should be borne in mind
that these viral proteins are acting in the context of each other. For ex-
ample, the ability of high-risk HPV E7 to target Rb for degradation can
trigger cell death but the ability of high-risk HPV E6 to target p53 for
degradation abrogates this death.
HPV overview
Establishing the oncogenic potential of high-risk HPVs and limited
oncogenic potential of low-risk HPVs
In the early 1980s several HPV genomes were isolated, some from
benign lesions and others from cervical carcinomas. Subsequent epide-
miological data established the grouping of HPV genomes into high-risk
(e.g., HPV 16, 18, 31, 33, 45) and low-risk (e.g., HPV 6, 11) with respect
to cancer (zur Hausen, 2002). Co-incident with the accumulation of
epidemiological data, the oncogenic potential of HPVs was deﬁned in
the late 1980s and early 1990s through a variety of in vitro assays. Initial
experiments established that high-risk HPVs could morphologically
transform permanent rodent cells (Tsunokawa et al., 1986; Yasumoto
et al., 1986). Further, high-risk HPVs could cooperate with activated
ras to transform primary rodent cells (Matlashewski et al., 1987).
As early as 1987 a distinction in the in vitro activity of high-risk ver-
sus low-risk HPV genomes was reported. High-risk HPVs could cooper-
ate with activated ras to transform primary rodent cells but low-risk
HPVs could not (Storey et al., 1988). The high-risk HPV genome but
not the low-risk HPV genome could cooperate with activated ras, in
the presence of dexamethasone, to morphologically transform primary
rodent cells (Pater et al., 1988). In contrast, others reported that low-
risk HPVs could cooperate with ras to transform primary rodent cells
although requiring more time in culture (Cerni et al., 1990; Chesters
and McCance, 1989). Some differences in outcome from different labo-
ratories probably relate to whether or not selection was used to isolate
transformed colonies and the assays used to score transformation.
The ability to conduct experiments in the HPV host cell, human
primary foreskin keratinocytes, led to exploration of HPV activity in
these latter cells. It was quickly shown that DNA from high-risk
HPVs could immortalize primary human keratinocytes derived from
foreskin or cervical tissue but that such cells were not tumorigenic
in nude mice (Kaur and McDougall, 1988; Pirisi et al., 1988; Pirisi et
al., 1987; Woodworth et al., 1988). Such cells became tumorigenic if
kept in culture for a period of time or if activated ras was introduced
(DiPaolo et al., 1989; Hurlin et al., 1991; Pecoraro et al., 1991). Fur-
ther, the high-risk HPV genome could alter differentiation of an orga-
notypic raft culture (McCance et al., 1988). The ability of HPVs to
immortalize human primary keratinocytes and inhibit differentiation
was initially reported to be limited to high-risk HPVs (Pecoraro et al.,
1989; Schlegel et al., 1988; Woodworth et al., 1989). However, later
experimental protocols indicated that low-risk HPVs could also
delay or alter differentiation (Thomas et al., 2001).
Deﬁning the oncogenes
Analysis of cervical carcinomas indicated that the high-risk HPV ge-
nome is often integrated and E6 and E7 are the genes that are expressed
(Schwarz et al., 1985; Yee et al., 1985). Later experiments showed that
the integration enhanced their activity (Jeon et al., 1995). Almostsimultaneouslywith the establishment that high-risk HPVs could trans-
form permanent rodent cells and cooperate with activated ras to trans-
form primary rodent cells, was the documentation that the critical
genes for this transformation were E6 and E7 (Bedell et al., 1987;
Vousden et al., 1988), with E7 having stronger transforming activity
(Vousden and Jat, 1989). Early on there was some controversy over
whether the E6 and E7 genes of low-riskHPVs had transforming activity
in rodent cells (Chesters and McCance, 1989; Hiraiwa et al., 1993;
Storey et al., 1990b). Some differences in outcomemay have been relat-
ed to the level of expression of proteins, either because of the promoter
used to drive expression or because of the level of splicing achieved.
Later experiments tended to use retroviral transduction, which also in-
ﬂuences the extent of splicing but also allows delivery of the genome to
a much higher percentage of cells compared to transfection.
In human keratinocytes, transfection of the E6 and E7 genes of
high-risk HPVs is necessary and sufﬁcient for immortalization and in-
hibition of keratinocyte differentiation but not for tumorigenicity
(Barbosa and Schlegel, 1989; Hawley-Nelson et al., 1989; Hudson
et al., 1990; Kaur et al., 1989; Munger et al., 1989a; Sedman et al.,
1991). The relative contribution of E6 and E7 to immortalization of
keratinocytes has also been examined using retroviral vectors. With
that protocol, E7, but not E6, alone can immortalize cells; however,
the efﬁciency of immortalization is much greater when E6 and E7
are expressed together (Halbert et al., 1991).
In contrast, low-risk HPV E6 and E7 have little or no immortalizing
activity. When transfected into keratinocytes, neither can comple-
ment the corresponding gene from HPV 16 or HPV 18 (Barbosa
et al., 1991). In addition, neither gene is able to immortalize keratino-
cytes when transduced into cells (Halbert et al., 1991). However, by
transduction, weak immortalizing activity of HPV 6 E6 or HPV 6 E7
can be detected when HPV 16 E7 or HPV 16 E6, respectively, is pre-
sent (Halbert et al., 1992).
Two issues arose during the course of these experiments. First, the
transcription and translation of E6 and E7 are regulated differently
between the high-risk and low-risk HPVs. While low-risk HPVs have
a promoter upstream of the E6 gene and another upstream of the
E7 gene, in high-risk HPVs there is a single promoter upstream of
E6 and a polycistronic mRNA is produced (Smotkin et al., 1989). Fur-
ther, in the high-risk HPVs, the relative levels of translation of E6 and
E7 are determined by whether the splice site within E6 is used, which
favors production of E7 (Sedman et al., 1991; Tang et al., 2006). Thus
it was possible that in instances where E6 seemed less active, this is
due to the level of expression of E6 versus E7 and similarly where
low-risk proteins seem less active, it could be due to differences in ex-
pression levels compared to high-risk. However, when the early re-
gion of both high-risk HPV and low risk HPV is expressed from a
strong promoter, only the high risk HPV early region can immortalize
keratinocytes (Morgan et al., 1992). Similarly, expression of individu-
al genes from the same promoter supports the conclusion that the
low-risk HPV E6 and E7 genes encoded proteins lacking in oncogenic
potential (Barbosa et al., 1991). Second, early data indicated that pre-
dominantly high-risk spliced mRNA was seen in patient biopsies and
immortalized cell lines (Bohm et al., 1993; Doorbar et al., 1990;
Sherman et al., 1992). In contrast, when cloned into a retrovirus, the
predominant mRNA species is unspliced. This is dictated by the dis-
tance between the promoter and splice donor (Zheng et al., 2004).
The potential differences in relative levels of E6 and E7 expression
depending upon the model system used should be kept in mind.
Finally, transgenic mouse models have validated the oncogenic
potential of high-risk alpha-HPV E6 and E7 in the skin, cervix, and
head and neck and the beta-HPV E6 and E7 in the skin (Dong et al.,
2005; Lambert et al., 1993; Riley et al., 2003; Strati et al., 2006).
These models have also revealed that the relative impact of E6 and
E7 in vivo is HPV type and tissue-speciﬁc. For example, alpha-HPV
E7 is the more potent oncogene in the cervix and head and neck but
alpha and beta-HPV E6s are more potent in the skin (Herber et al.,
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and Lambert, 2007). There are no published results on the activity of
low-risk HPV E6 and/or E7 in the transgenic mouse model.
The HPV E6 proteins
E6 and transformation
While E6 and E7 are co-expressed in the course of HPV infection
and in cancers, dissection of the individual contribution of each onco-
gene is important for determining their role in replication and trans-
formation. While a number of E6 functions and interactions help to
explain how high-risk HPV E6s cause transformation, surprisingly few
functions have been attributed to E6s from low-risk types. Those that
are shared between low- and high-risk HPV E6s might point to what
functions are important for the virus life cycle. In the following sections,
high and low risk E6s will be compared when the information is avail-
able. Of course, because of the association with development of cancer,
most studies have focused on high-risk HPV E6s.
E6s from high-risk types such as HPV 16 and 18 have transforming
potential in various assays. Early studies indicated that high-risk HPV
E6s are not particularly effective in cooperating with activated ras to
cause transformation of baby rat kidney (BRK) cells (Bedell et al.,
1989; Phelps et al., 1988; Sedman et al., 1991; Storey et al., 1988).
Taking the cue from SV40 T antigen and adenovirus E1B, researchers
determined that high-risk HPV E6 binds to p53 (Werness et al., 1990).
Later it was shown that E6 targets p53 for degradation (see below)
(Scheffner et al., 1990). These ﬁndings spawned a great deal of inter-
est in E6 and its involvement in transformation. While early studies
suggested that p53 mutation and E6 expression were equivalent in
the transformation of mouse cells in cooperation with mutant ras
(Storey and Banks, 1993), the ﬁnding that certain E6 mutants are un-
able to target p53 for degradation but still have transforming proper-
ties indicated that E6 has other functions (Pim et al., 1994; Storey and
Banks, 1993). E6 from high-risk types does not cause immortalization
of human keratinocytes on its own but signiﬁcantly increases the ef-
ﬁciency of immortalization of human keratinocytes by high-risk
HPV E7 (Halbert et al., 1991, 1992; Howley and Lowy, 2007). In ap-
parent contrast to these ﬁndings, high-risk HPV E6 alone can immor-
talize human mammary epithelial cells (Band et al., 1991; Dalal et al.,
1996). However, it was later demonstrated that loss of expression ofTable 1
Functions of HPV E6.
Function High-risk HPV E6
(HPV 16, 18, or 31)
Inhibition of p53 transactivation +
Inhibition of p53 acetylation +
Bypass of growth arrest upon DNA damage +
Induction of genetic instability +
Immortalization of human cells (with Rb inactivation) +
Telomerase activation +
c-myc activation +
Inhibition of keratinocyte differentiation +
Inhibition of interferon response +
NF-κB activation +
Akt activation +
Wnt activation +
mTORC1 activation +
miR-34a downregulation +p16Ink4a, a cyclin dependent kinase inhibitor, along with E6 expres-
sion is necessary for mammary epithelial cell immortalization, indi-
cating a requirement for abrogation of the Rb pathway (Foster et al.,
1998; Kiyono et al., 1998). Degradation of p53 is not essential for im-
mortalization of human keratinocytes and mammary epithelial cells
(Kiyono et al., 1998; Liu et al., 1999) and, in fact, immortalization of
these cells is more associated with the ability of E6 to activate telome-
rase (discussed below) (Kiyono et al., 1998). Low-risk HPV E6s have
little to no transforming or immortalizing potential in transformation
assays (Band et al., 1993; Halbert et al., 1992).
Studies with transgenic animals have also provided insight into
how high-risk HPV E6s cause transformation. In transgenic mice
that express high-risk HPV E6 and E7 from a keratin 14 (K14) pro-
moter, tumors develop in the skin and cervix, the latter in conjunc-
tion with chronic estrogen treatment (Riley et al., 2003; Song et al.,
1999). These studies demonstrate that both oncogenes have trans-
forming properties in vivo. While the E6 transgene plus estrogen
can cause tumors, similar studies with the E7 transgene show that it
is more efﬁcient at tumor initiation. E6 may be more important for
tumor progression (Riley et al., 2003). In these studies with transgen-
ic animals, two functions of E6 emerged as being important for tu-
morigenicity, the ability to bind to alpha-helix containing proteins
and the ability to bind to PDZ (PSD95/Dlg/Zo-1) containing proteins
(Shai et al., 2007).
Overall, these ﬁndings indicate that high-risk HPV E6s cooperate
with abrogation of the Rb pathway (either through expression of E7
or other mechanisms) to cause transformation. Furthermore, they
demonstrate that high-risk HPV E6s have multiple functions, aside
from targeting p53 for degradation, that are important for transfor-
mation. They do not, however, tell us much about the role of E6 in
virus replication.
Many different functions have been attributed to E6 (Table 1) and
it has been shown that E6 has numerous interactions within the cell
including both DNA binding properties and the ability to bind to
many cellular proteins (Table 2). For recent reviews, see Howie et
al. (2009); Liu et al. (2009); Pim and Banks (2010); Wise-Draper
and Wells (2008); and Yugawa and Kiyono (2009). In this part of
the review, functions and transformation properties of E6 will be dis-
cussed. Where applicable, comparisons will be made between those
functions and binding partners that are shared between low- and
high-risk HPV E6s, with the thought that this will shed light onLow-risk HPV E6
(HPV 6 or 11)
References
+ Crook et al. (1991); Lechner and Laimins (1994);
Pim et al. (1994); Thomas et al. (1995)
+ Jha et al. (2010); Patel et al. (1999);
Thomas and Chiang (2005)
− Havre et al. (1995); Jones and Munger (1997);
Kessis et al. (1993)
? Duensing and Munger (2002); Liu et al. (2007)
− Dalal et al. (1996); Halbert et al. (1991)
− Gewin and Galloway (2001); Kiyono et al. (1998);
Klingelhutz et al. (1996); Veldman et al. (2001)
− Veldman et al. (2003)
? Alfandari et al. (1999); Duffy et al. (2003);
Nees et al. (2000); Sherman et al. (1997);
Sherman and Schlegel (1996)
+/− Cordano et al. (2008); Li et al. (1999);
Nees et al. (2001); Ronco et al. (1998)
? An et al. (2008); James et al. (2006b);
Nees et al. (2001); Yuan et al. (2005)
? Pim et al. (2009)
? Lin et al. (2009)
? Spangle and Munger (2010)
? Wang et al. (2009b)
Table 2
Binding partners of HPV E6.
Binding
partner
High-risk (16, 18 or 31) Low-risk (1, 6 or 11) References
p53 + (binding and degradation) +/− (binding) Crook et al. (1991); Foster et al. (1994); Lechner and Laimins (1994);
Li and Cofﬁno (1996); Pim and Banks (1999); Pim et al. (1997);
Scheffner et al. (1990); Thomas et al. (1995); Werness et al. (1990)
E6-AP + (binding) + (11E6 binds) Bedard et al. (2008); Brimer et al. (2007); Scheffner et al. (1993)
Bak + (binding and degradation) + (binding and degradation) Thomas and Banks (1999); Underbrink et al. (2008)
Dlg + (binding and degradation) +/− (degradation) Brimer et al. (2007); Gardiol et al. (1999); Kiyono et al. (1997);
Pim et al. (2009)
MAGI-1 + (binding and degradation) − Pim et al. (2009); Thomas et al. (2002)
MAGI-2 + (binding and degradation) − Pim et al. (2009)
MUPP1 + (binding and degradation) − Lee et al. (2000)
Scribble + (binding and degradation) − Nakagawa and Huibregtse (2000); Pim et al. (2009)
CAL + (binding and degradation) ? Jeong et al. (2007)
PTPN3/PTPN13 + (binding and degradation) − Jing et al. (2007); Spanos et al. (2008b)
p300/CBP + (binding prevents acetylation of p53) +/− (binding prevents acetylation of p53) Patel et al. (1999); Thomas and Chiang (2005);
Zimmermann et al. (1999)
Tip60 + (destabilizes) + (destabilizes) Jha et al. (2010)
PML + (interaction) + (interaction) Guccione et al. (2004)
E6TP1 + (binding and degradation) − Gao et al. (1999)
Paxillin + (binding) − Tong et al. (1997)
E6BP/ERC-55 + (interaction) ? Chen et al. (1995)
Mcm7 + (binding and degradation) − Kuhne and Banks (1998); Kukimoto et al. (1998)
MGMT + (binding and degradation) ? Srivenugopal and Ali-Osman (2002)
NFX1-91 + (binding and degradation) − Gewin et al. (2004); Xu et al. (2008)
TERT + (binding) ? Liu et al. (2009)
Ada3 + (binding and degradation) − Kumar et al. (2002)
Tyk2 + +/− Li et al. (1999)
FADD + (binding and degradation) ? Filippova et al. (2004)
TNFR1 + (binding) ? Filippova et al. (2002)
IRF-3 + (16 only, inhibits transactivation) − Ronco et al. (1998)
Procaspase 8 + (degradation) − Filippova et al. (2007); Tungteakkhun et al. (2010)
c-myc + (co-activation) − Veldman et al. (2003)
CYLD + (binding and degradation) ? An et al. (2008)
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edge on the function of E6s from beta-PVs will be discussed in a sec-
tion devoted to beta-PVs toward the end of the review.
Features of the E6 protein
The E6 protein is approximately 150 amino acids in length with a
molecular weight of 18 kDa (Howley and Lowy, 2007). E6 proteins
from different HPV types are characterized by four C-X-X-C motifs
that are involved in the formation of two zinc binding sites (Fig. 1).
These zinc binding sites are essential for many of the known functionsFig. 1. Schematic of the HPV 16 E6 protein. The two zinc binding sites are conserved among t
the schematic displays the aligned sequences of high-risk HPV 6 E6 and low-risk HPV 16 Eof E6, although there are some exceptions. A region in the second zinc
binding site of E6 is involved in binding to a number of alpha-helix
containing cellular proteins that have an LXXLL motif, including the
ubiquitin ligase, E6-AP (Chen et al., 1998). In addition to this domain,
other regions of E6 are important for various E6 functions and for
binding to cellular proteins such as p53, E6-AP, p300, and PDZ-
containing proteins. These will be discussed in more detail below.
Determining the exact structure of E6 has been difﬁcult. In one
study, the N and C terminal halves were separated and folded inde-
pendently such that a pseudodimeric scaffold was predicted for the
whole E6 protein (Nomine et al., 2006). Both the N and C terminihe different HPV types. Protein binding regions are shown for HPV 16 E6. The text below
6.
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stranded beta sheet and two short helices. Antiparallel assembly of
the N and C termini leads to a six-stranded beta sheet with the two
H1 helices packing in a classical manner and the zinc binding sites lo-
cated at opposite edges of the molecule. In this model, a number of
conserved residues are exposed in all HPV species that could be in-
volved in structure or generic function. Using a combination of soft-
ware programs to predict ordered and disordered regions of
proteins, high-risk HPV E6 is found to be more disordered (unfolded)
than low-risk HPV E6 (Uversky et al., 2006), consistent with the ﬁnd-
ing that oncogenic proteins are more disordered.
E6 can be localized to both nuclear, cytoplasmic, and membrane
fractions (Grossman et al., 1989; Guccione et al., 2002), a ﬁnding
which supports its many proposed functions. There is evidence that
E6 localization is different for low- and high-risk viruses and that
this might partially explain differences in the way low and high-risk
HPV E6 regulates cellular proteins such as p53 (Guccione et al.,
2002; Pietsch and Murphy, 2008). For example, rather than targeting
p53 for degradation, low-risk HPV E6s apparently sequester p53 in
the cytoplasm to prevent it from transactivating p53 responsive
genes in the nucleus (Pietsch and Murphy, 2008).
The understanding of E6 function is further complicated by the
fact that certain high-risk HPV types generate one or more truncated
E6 transcripts, called E6*. The proteins generated from these tran-
scripts have their own inhibitory or activating functions (Filippova
et al., 2007; Pim and Banks, 1999; Pim et al., 1997). For example,
E6* inhibits E6-mediated degradation of p53 by binding the full-
length E6 protein (Pim and Banks, 1999). E6* has also been shown
to modulate how E6 affects apoptotic pathways (Filippova et al.,
2009). Other functions of E6* have also been demonstrated as dis-
cussed below.
Interactions with p53 and E6-AP
Certainly, one of the best-known functions of E6 from high-risk
HPV types is the binding and targeting of p53 for ubiquitin-
mediated degradation (Scheffner et al., 1990). The ubiquitin ligase in-
volved in this process is E6-AP (E6 associated protein) (Huibregtse et
al., 1991; Scheffner et al., 1993). E6 domains necessary for binding
and degradation of p53 are different, although the exact nature of
these interactions has a history of controversy (Crook et al., 1991;
Foster et al., 1994; Li and Cofﬁno, 1996; Pim et al., 1994; Thomas et
al., 1995). Both low- and high-risk HPV E6s can bind to p53 through
E6's C-terminal half but this does not induce degradation (Lechner
and Laimins, 1994). Binding to the N-terminal half of E6 is necessary
for p53 degradation. Two different regions of p53 can be bound by E6,
a region in the carboxy terminus that is bound by both low-and high-
risk HPV E6's, and a region in the core region that correlates with p53
degradation (Li and Cofﬁno, 1996). Binding to the core of p53 is nec-
essary for degradation. The exact nature of E6's binding to E6-AP is
also not entirely clear. However, it would appear that more than
one region is necessary for effective binding (Huibregtse et al.,
1993; Nomine et al., 2006; Pim and Banks, 2010). There is evidence
that E6 from low-risk HPV 11 can also bind E6-AP (Brimer et al.,
2007), indicating that E6-AP binding and p53 degradation are not al-
ways associated with one another and suggesting a potentially im-
portant role for binding of E6-AP by low and high risk E6s.
Other mechanisms of p53 pathway abrogation by low- and high-risk
HPV E6s
Even though low-risk HPV E6s do not effectively target p53 for
degradation they are capable of abrogating p53's function in other
ways (Lechner and Laimins, 1994). For example, as mentioned
above, low-risk HPV E6s may sequester p53 in the cytoplasm to affect
function (Pietsch and Murphy, 2008). In addition, low-risk HPV E6scan also inhibit transcriptional activation by p53. Like high-risk HPV
E6s, low-risk HPV E6s are capable of interacting with the p300/CBP
complex, which is involved in p53 acetylation and this interaction
does not involve E6-AP (Patel et al., 1999; Thomas and Chiang,
2005; Zimmermann et al., 1999). The binding is thought to prevent
the acetylation of p53. Indeed, expression of E6 proteins represses
the ability of p53 to activate p53 responsive promoters. While there
have been conﬂicting reports over how low-risk HPV E6s affect p53
transactivation, some of the controversy is likely due to use of differ-
ent p53 promoters (Pim and Banks, 2010). p53 is modiﬁed in a vari-
ety of ways (e.g. acetylation and phosphorylation) and many of
these modiﬁcations affect the ability of p53 to differentially modulate
the activity of different promoters. Other potential mechanisms have
been proposed to explain how E6 affects acetylation of p53. For exam-
ple, E6 can bind Ada3, another HAT, but this interaction has not been
extensively studied for low-risk HPV E6 (Kumar et al., 2002).
Recently, a new interaction of both low- and high-risk HPV E6s
with the nucleosomal acetyltransferase TIP60 has been demonstrated
that also offers further insight into how E6 affects p53 function (Jha et
al., 2010). TIP60 is involved in a number of processes including acet-
ylation of histone H4, acetylation of p53 at K120, and, indirectly, in
dephosphorylation of phosphoH2AX for termination of DNA damage
response (Sun et al., 2010). E6's interaction with TIP60 destabilizes
the TIP60 complex and causes disruption of TIP60-dependent tran-
scriptional regulation and apoptosis. Interestingly, E6 affects the abil-
ity of TIP60 to mediate p53-associated upregulation of genes involved
in inducing apoptosis, but it does not affect p53-associated upregula-
tion of cell cycle arrest genes such as p21WAF. In addition, TIP60 sup-
presses the HPV early promoter through binding to a Brd4 complex.
E6's interaction with TIP60 ameliorated this effect. Another ﬁnding
of this study is that E6's effect on TIP60 does not depend on binding
to E6-AP or p53. In fact, E6*, which consists of only the ﬁrst 43
amino acids of E6, modulates and causes destabilization of TIP60.
Thus, these studies shed new light on how E6 from both low- and
high-risk types regulate p53. Understanding E6's interaction with
TIP60 might be a key to understanding how E6 is involved in the
HPV life cycle, but further studies using HPV replication assays are
warranted.
p53 and viral replication
The role of E6 in the HPV life cycle is not entirely clear, but studies
using the entire HPV 11, 16 or 31 genomes have demonstrated that E6
is necessary for efﬁcient replication in keratinocytes (Oh et al., 2004;
Park and Androphy, 2002; Thomas et al., 1999). HPV 16 E6 mutants
defective in p53 binding are loss of function for genome maintenance
(Park and Androphy, 2002). For HPV 11, lack of E6 results in rapid loss
of episomal forms of the viral genome and mutation of a p53 binding
site in HPV 11 E6 results in inability to maintain episomes (Oh et al.,
2004). Similar ﬁndings are observed for HPV 31 (Park and
Androphy, 2002). A more recent study, using a raft culture system, in-
dicated that lack of E6 results in p53 accumulation and a severe re-
duction in genome ampliﬁcation during the productive stage of
replication. In this setting, genome ampliﬁcation is rescued by retro-
viral transduction of E6 (Wang et al., 2009a). Thus, it appears that
E6 is essential for replication, most likely playing a signiﬁcant role
in the productive program, and that abrogation of p53, but not neces-
sarily degradation, is important in this process.
Because both low- and high-risk HPV E6 inhibit the p53 pathway,
it would certainly appear that this is an important concern for papil-
lomaviruses, as it is for other viruses. The abrogation of key p53 func-
tions is predicted to have signiﬁcant consequences with regard to
DNA damage response, apoptosis, and cellular transformation. The
mechanism by which the different E6s inhibit p53 function could
greatly affect the ability of p53 to confer either apoptosis or cycle ar-
rest. E6s from high-risk virus types appear to have a much greater
82 A.J. Klingelhutz, A. Roman / Virology 424 (2012) 77–98capacity than E6s from low-risk virus types to bypass cell cycle arrest
and prevent apoptosis and part of this is likely due to their more efﬁ-
cient ability to abrogate p53 function (Elbel et al., 1997; Foster et al.,
1994). There is no deﬁnitive evidence that high-risk viruses replicate
“better” than low-risk viruses, so the reason for the different mecha-
nisms of p53 abrogation is unclear. One possibility is that E6 is neces-
sary for counterbalancing the effects of E7, which by itself is known to
upregulate p53 (Demers et al., 1994b). With this in mind, it is tempt-
ing to speculate that high-risk HPV E6s might have to be more effec-
tive at abrogating the p53 response because high-risk HPV E7 is more
prone to activating it. However, there are also studies that indicate
that high-risk HPV E7 stabilizes p53 without activating it and that
high-risk HPV E7 might also inhibit p53 activity (Eichten et al.,
2002; Jones et al., 1999). Thus, a simple explanation is not readily
apparent.
E6 and Bak
In addition to E6's role in affecting the p53 pathway, E6 also di-
rectly affects apoptotic effector molecules and this appears to be con-
served between low- and high-risk virus types. For example, both
low- and high-risk HPV E6s bind to the pro-apoptotic protein, Bak,
and cause its degradation (Thomas and Banks, 1999). This p53-
independent interaction may affect responses to DNA damaging
agents such as UV (Jackson and Storey, 2000). These ﬁndings suggest
that E6's interaction with Bak is conserved across many HPV types
and would indicate that it is important for the HPV life cycle.
E6 and PDZ containing proteins
Another important function of high-risk HPV E6s that has been
given a lot of attention is its ability to bind to PDZ containing pro-
teins through its C-terminal PDZ binding motif (Thomas et al.,
2008). PDZ binding motifs are also found in many other viral pro-
teins including HTLV-1 tax and adenovirus E4-ORF1 (Javier, 2008).
This generality would suggest that high-risk papillomaviruses bene-
ﬁt from modulating these proteins for efﬁcient replication. The PDZ
binding motif of E6 is essential for transformation in vitro and in
vivo, both in transgenic mouse models and in a xenograft model
of HPV-associated oropharyngeal cancer (Simonson et al., 2005;
Spanos et al., 2008b). The PDZ binding motif has also been implicat-
ed in causing an epithelial to mesenchymal transition in human ep-
ithelial cells (Watson et al., 2003), in activating NFκB (James et al.,
2006b) and in increasing the efﬁciency of immortalization of
human tonsillar epithelial cells (Spanos et al., 2008a). Numerous
proteins contain PDZ domains and E6 binds to many of them to
cause their degradation (see Table 2). Several PDZ containing pro-
teins that bind to E6 belong to the MAGUK (Membrane Associated
Guanylate Kinase) family of proteins (e.g. Dlg, Scribble, and MAGI-
1, -2, and -3) which are generally believed to be associated with
the cellular membrane and affect such processes as cell polarity,
maintaining cell-to-cell interactions, and mediating signals from
membrane (Gardiol et al., 1999; Jeong et al., 2007; Kiyono et al.,
1997; Nakagawa and Huibregtse, 2000; Thomas et al., 2002). The
E6 PDZ motif is also important for binding to several protein phos-
phatases (e.g. PTPN3 and PTPN13) that are believed to be involved
in both inhibiting and activating a variety of cell signaling pathways
(Jing et al., 2007; Spanos et al., 2008b). These phosphatases are also
commonly mutated or downregulated in cancer and E6-mediated
degradation of the phosphatases appears to be necessary for tumor-
igenic transformation by E6 (Spanos et al., 2008b). A recent study
indicated that downregulation of PTPN13 by E6 is associated with
activation of MAP kinase signaling (Hoover et al., 2009).
While the PDZ binding motif is conserved among high-risk virus
types, the motif is generally not found in low-risk HPV E6's. Swapping
the PDZ domain of high-risk HPV E6 onto low-risk HPV E6 results indegradation of PDZ containing proteins (Pim et al., 2002). The E6 pro-
tein of some so-called low-risk HPV types such as HPV-70 can bind to
PDZ domain containing proteins (Muench et al., 2009). In addition,
HPV-18 E6* (which does not contain a PDZ binding motif) causes
the downregulation of many PDZ proteins such as Dlg, without a di-
rect interaction between the two proteins, although the proteasome
pathway is apparently involved (Pim et al., 2009). These studies indi-
cate that inactivation of PDZ containing proteins is not exclusive to
full-length high-risk HPV E6s and that the different viral types may
have adapted different strategies to deal with these proteins. Like
the interaction of E6 with p53, the different mechanisms by which
the virus manipulates the PDZ containing proteins may determine
whether the virus causes cancer or not. Further studies are warranted
to determine whether inhibition of PDZ containing proteins is impor-
tant for replication of high-risk viruses.
E6 and keratinocyte differentiation
Modulation of keratinocyte differentiation by E6 is a potential
mechanism that HPVs might utilize to make the cellular environment
more favorable for replication. E6s from high-risk types inhibit serum
and calciummediated differentiation (Alfandari et al., 1999; Sherman
and Schlegel, 1996). Microarray analyses demonstrate that E6 expres-
sion causes downregulation of a large number of genes that are asso-
ciated with keratinocyte differentiation (Duffy et al., 2003; Nees et al.,
2000). Evidence suggests that E6 inhibits differentiation through
downmodulation of the TGF-beta pathway (Nees et al., 2000). In ad-
dition, high-risk HPV E6s bind to cellular proteins such as ERC-55, a
calcium binding protein, E6-TP1, a Rap1 GTPase-activating protein,
and paxillin, a focal adhesion protein, all of which could play a role
in altering the differentiation capacity of keratinocytes (Chen et al.,
1995; Gao et al., 1999; Tong et al., 1997). More recently, high-risk
HPV E6 was found to alter the Notch pathway, which is a well-
studied effector of keratinocyte differentiation (Chakrabarti et al.,
2004). One would expect that low-risk HPV types would also beneﬁt
from modulating cellular differentiation, but most of the interactions
noted above are limited to E6s from high-risk types and studies impli-
cating low-risk HPV E6s in modulating differentiation are insufﬁcient
for drawing conclusions.
E6 and NFκB activation
Another potentially important function of E6 in modulating the
host cell environment is its ability to activate the NFκB pathways. Ac-
tivation of NFκB has been demonstrated in most epithelial cancers
where it is believed to play a role in a variety of cellular processes in-
cluding inhibition of apoptosis, adaptation to hypoxia and epithelial
to mesenchymal transition (EMT), among other possibilities
(Prasad et al., 2010). Microarray analyses indicate that E6 activates
a large number of NFκB responsive genes (Nees et al., 2001) and
other studies demonstrate that E6 upregulates the NFκB responsive
gene c-IAP2 to confer resistance to apoptosis (James et al., 2006b;
Yuan et al., 2005). The mechanism by which E6 activates NFκB is
not completely clear. One study indicated that the PDZ binding
motif is involved (James et al., 2006b), whereas another study pro-
vided evidence that E6 inactivates a deubiquitinase called CYLD,
which subsequently causes activation of the NFκB pathway during
hypoxia (An et al., 2008). Further, E6 activates NFκB by interactions
with the transcription factor NFX1-91 (Xu et al., 2010). Whether
E6's from low-risk HPV types interact with either CYLD or NFX1-91
is currently unknown.
E6 and PMLs
It has been demonstrated that both low-risk and high-risk HPV E6
can abrogate PML (promyelocytic leukemia) induced cellular
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tion of PML in primary baby rat kidney cells (Guccione et al., 2004).
The interaction of E6 with PMLs is conserved across low- and high-
risk viruses, indicating that it may be important for the viral life
cycle. PML proteins are present in nuclear bodies referred to as
PODs (PML oncogenic domains) or nuclear domain 10 (ND10)
(Guccione et al., 2004). These subnuclear bodies are attached to the
nuclear matrix and are believed to play a role in many cellular pro-
cesses such as transcriptional regulation, protein modiﬁcation, apo-
ptosis, senescence, interferon response, autophagy, and chromatin
modiﬁcations. Other nuclear proteins in PODs include Daxx, Sp100,
and CBP. PODs have been implicated in cellular defense mechanisms
against viral replication or, on the other hand, as possible sites for
viral assembly for a variety of different viruses (Schiller et al., 2010).
The HPV late protein L2 associates with PODs, suggesting that PODs
may play a role in papillomavirus life cycle (Lin et al., 2009; Schiller
et al., 2010). Another study suggests that PODs do not play a signiﬁ-
cant role in HPV replication (Nakahara and Lambert, 2007). Further
research will be needed to resolve this controversy.
A new function for E6: activation of mTORC1
An additional high-risk HPV E6 function that has recently been
demonstrated is its ability to regulate the mTORC1 pathway
(Sabatini, 2006; Spangle and Munger, 2010). The mechanism by
which this occurs is not entirely clear. Early studies indicated that
the E6 protein caused degradation of the mTOR inhibitor TSC2 (tu-
berous sclerosis complex 2) (Lu et al., 2004; Zheng et al., 2008),
but this ﬁnding was not repeated in more recent studies (Spangle
and Munger, 2010). However, E6 increases protein synthesis by en-
hancing translation initiation complex assembly at the 5′ mRNA cap
and increasing cap-dependent translation. This is likely due to
mTORC1 activation; co-expression of E7 did not appear to affect
this function. These ﬁndings suggest that E6 is involved in modulat-
ing cellular metabolism and could have signiﬁcant implications for
the potential role of E6 in promoting viral replication in differentiat-
ed cells, where nutrient supply would be low. Whether this function
of E6 is conserved across different HPV types remains to be
determined.
E6 and the cell cycle
Because HPVs replicate in terminally differentiating tissue, they
have developed a number of strategies to push normally nondivid-
ing cells into states that allow DNA synthesis. As mentioned above,
the abrogation of the p53 pathway by E6s allows bypass of p53-
mediated checkpoints in the context of DNA damage or apoptotic
signaling. As will be discussed, HPV E7 interferes with Rb signaling
to mediate the transit of cells from G1 to S. There is also evidence
that HPV E6 plays a direct role in this process. In human ﬁbroblasts,
expression of E6 causes phosphorylation of Rb along with concom-
itant upregulation of genes that are normally inhibited by Rb such
as p16INK4a, CDC2, E2F-1, and cyclin A (Malanchi et al., 2004). E6
expression is also associated with an increase in cyclin A/cyclin de-
pendent kinase activity. In this context, p53-independent downre-
gulation of the cyclin/cdk inhibitor p21CIP1 is also observed.
Interestingly, these activities were demonstrated for HPV 16 E6
and HPV 1 E6, indicating that both non-oncogenic and oncogenic
E6s are involved in promoting G1 to S transit. Another study showed
that in the transgenic mouse model high-risk HPV E6 causes upregu-
lation of E2F responsive (e.g. S phase) genes such as Mcm7 and cyclin
E (Shai et al., 2007). There is also evidence that high-risk HPV E6 can
bind directly to Mcm7 (Kukimoto et al., 1998). Overall, these ﬁndings
indicate that E6 plays a role in pushing cells into S phase and that
this is not necessarily dependent on abrogation of the p53 path-
way. Moving cells into S, particularly when DNA damage hasoccurred or when the cell is not ready to replicate its DNA would
be expected to lead to chromosome instability. Indeed, high-risk
HPV E6 and E7 can independently induce numerical and structural
chromosome instability (Duensing and Munger, 2002) and E6 can
cause polyploidy by a p53-independent mechanism (Heilman et
al., 2009). The consequences of this instability could be an in-
creased chance for development and progression of cancer.
E6 and interferon response
Most viruses have evolved mechanisms to avoid or repress the in-
terferon response and papillomaviruses are no exception. Microarray
studies indicate that expression of E6 causes downregulation of mul-
tiple IFN responsive genes including Stat-1 and 2′-5′ oligoadenylate
synthetase and downregulation of IFN-α and -β (Nees et al., 2001).
The E6 protein from both high- and low-risk HPV E6 binds to Tyk2
of the Jak–Stat pathway but only high-risk HPV E6 inhibits its func-
tion (Li et al., 1999). High-risk HPV E6 also binds interferon regulato-
ry factor-3 (IRF-3) and inhibits its ability to activate transcription of
IFN-β responsive genes (Ronco et al., 1998). Whether downregula-
tion of the interferon response is an integral part of HPV infection
and replication is not entirely clear. Both E6 and E7 and another
viral protein, E1, are thought to play a role in suppressing the IFN re-
sponse (Beglin et al., 2009) so the situation is complicated. The ability
of E6 to mediate resistance to IFN induced growth arrest is dependent
on inhibition of p53 acetylation by p300/CBP (Hebner et al., 2007).
Since low-risk HPV E6s are capable of interacting with p300/CBP, it
would seem likely that low-risk HPVs would be capable of suppres-
sing the IFN response upon infection, but this remains to be
determined.
E6 and telomerase
As mentioned above, exogenous expression of high-risk but not
low-risk HPV E6s activates telomerase, the enzyme that adds telo-
mere repeats to the ends of chromosomes (Klingelhutz et al., 1996).
Telomerase activation has also been demonstrated in cells with repli-
cating HPV genomes, indicating that this activation is not simply an
artifact of overexpression of E6 through retroviruses (Sprague et al.,
2002). The mechanism by which E6 activates telomerase is still not
completely clear. Mutational analyses indicate that activation does
not depend on p53 degradation or the PDZ binding motif (Kiyono
et al., 1998; Klingelhutz et al., 1996). Expression of E6 causes tran-
scriptional upregulation of TERT, the reverse transcriptase compo-
nent of telomerase, and acetylation of histones at the TERT
promoter is associated with this activation (Gewin and Galloway,
2001; Oh et al., 2001; Veldman et al., 2001). Initial studies indicated
that E6 activation of telomerase relied on a proximal E-box in the
TERT promoter. It was later demonstrated that E6 binds to c-myc
and E6-AP in a complex and, although this does not lead to degrada-
tion of c-myc, the interaction might allow c-myc to be more active at
the TERT promoter (Veldman et al., 2003). Other studies indicate that
E6 can bind to and target for degradation a cellular protein called
NFX1-91 that binds to mSin3a, a histone deacetylase that acts as a re-
pressor of TERT transcription in the TERT promoter (Gewin et al.,
2004; Xu et al., 2008). Splice variant NFX1-123 and cytoplasmic
poly(A) binding proteins may also play a role in regulating TERT
levels (Katzenellenbogen et al., 2009). While most mutational studies
have implicated E6-AP binding as being necessary for telomerase ac-
tivation by E6 (James et al., 2006a; Liu et al., 2005; Xu et al., 2008), a
conﬂicting report indicates that binding of E6 to E6-AP is not involved
in induction of telomerase (Sekaric et al., 2008). As discussed later in
this review, expression of E7 can synergize with E6 to increase telo-
merase levels (Liu et al., 2008). A more recent study provides evi-
dence that E6 can bind directly to the TERT protein, which could
stabilize TERT and/or change its localization in the cell (Liu et al.,
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function of E6 from high-risk types is essential for immortalization
of primary cells (Kiyono et al., 1998). Because E6s from low-risk
HPV types do not activate telomerase, the role that E6's activation of
TERT plays in the virus life cycle is unclear.
While TERT is involved in telomerase activation and telomere
elongation, TERT also has telomere-independent functions
(Bollmann, 2008), one of which is activation of the Wnt signaling
pathway (Choi et al., 2008). It is interesting to note that E6 can acti-
vate the Wnt pathway, although the mechanism is unknown
(Lichtig et al., 2010). Wnt signaling is involved in a variety of cellular
processes and it is possible that activation of this pathway creates a
cellular environment that is favorable for high-risk HPV replication.
Regulation of miRNAs by E6
The regulation of cellular miRNAs by viral proteins provides a po-
tent means to affect a number of cellular processes. Not surprisingly,
recent studies indicate that high-risk HPV E6 and E7 affect miRNAs
that are known to be involved in growth regulation (Zheng and
Wang, 2011). For example, high-risk HPV E6s downregulate miR-
34a, an miRNA that targets numerous genes involved in cell cycle
control (Wang et al., 2009b). High-risk HPV E6s also downregulate
expression of miR-23b, which targets expression of the urokinase
plasminogen activator gene, and subsequently may affect cell migra-
tion (Au Yeung et al., 2011). Much of high-risk HPV E6's ability to af-
fect miRNA expression is apparently through its ability to target p53.
A recent study, however, indicated that low-risk HPV-11 also modu-
lates miRNA expression (Dreher et al., 2011). Thus, there is the possi-
bility that both low and high-risk HPV E6 affect cell function,
differentiation, and growth through modulation of miRNAs.
Summary of E6
The precise role of E6 in the HPV life cycle has been difﬁcult to as-
certain, partly because it is so multifunctional, but also becauseFig. 2. Schematic of the HPV 16 E7 protein. The positions of CR1, CR2, and the zinc binding sit
conserved among the different HPV types. Protein binding regions are shown for HPV 16 E7.
HPV 16 E7. The PTLHE (6–10), DLYC (22–26) sequences referred to in the text are underline
HPV 6 E7 is in purple; the LXCXE motif in red; and the CKII recognition sequence in blue. T
79–83) and for binding HDAC is denoted by underlining and brown lettering, respectively.different HPV types have evolved into their own niches and have de-
veloped different strategies to efﬁciently replicate. Looking for com-
mon functions between E6s from different HPV types might provide
some insight into what is necessary for replication but it should be
kept in mind that each type has likely developed its own particular
ways to overcome cellular defenses and create the right cellular envi-
ronment for viral replication and maintenance. Even among the same
HPV types there is considerable variation. For example, recent studies
have demonstrated that a variant of HPV 16 with only minimal differ-
ences in E6 sequence from the prototype (Q14H/H78Y/L83V) is more
efﬁcient at immortalizing and transforming cells, even though p53
targeting and telomerase activation appear to be similar (Richard
et al., 2010). This variant is found more frequently in cervical cancers,
which may indicate that these amino acid alterations cause more ef-
ﬁcient transformation, better replication, maintenance, or a combina-
tion of these factors. Certainly, improved model systems to study HPV
replication as well as more rigorous comparisons between different
HPV types and subtypes will be necessary to advance our understand-
ing of the role of E6 in the HPV life cycle.
The HPV E7 proteins
E7 functions and posttranslational modiﬁcations recognized early
The E7 proteins range in size from 98 to 105 amino acids. The
structure of two HPV E7s determined by NMR and by X-ray crystal-
lography shows that the N-terminal half is disordered (extended)
while the C-terminal half forms a well structured zinc binding site
with a β1β2α1β3α2 topology (Liu et al., 2006; Ohlenschlager et al.,
2006). The designation of a disordered structure in the N-terminus
and an ordered structure in the C-terminus of E7 correlates with ob-
servations made on the disordered content of the E7 protein using a
number of software programs (Uversky et al., 2006). Of note, com-
pared to high-risk HPV E7s, the low-risk HPV E7s have a lower degree
of disorder, perhaps indicative of a lower number of interactions with
other proteins (see below) (Uversky et al., 2006). The N-terminus ofe, as well as the LXCXE motif and CKII site within CR2 are shown. The zinc binding site is
The text below the schematic displays the aligned sequences of high-risk HPV 6 E7 and
d; the amino acid conferring low or high Rb binding afﬁnity is italicized; the PKC site in
he proximity of the sequences required for abrogating p21CIP1 activity (aa 68–70 and
Table 3
Binding partners of HPV E7.
Binding partnera High-risk (HPV 16, 18, 31) Low-risk (HPV 6 or 11) References
Rb + (binding and degradation) bb(binding) Dyson et al. (1989b); Munger et al. (1989); Firzlaff et al. (1991);
Jones and Munger (1997); Berezutskaya et al. (1997);
Helt and Galloway (2001)
p107 + (binding and degradation) b (binding) Dyson et al. (1992); Helt and Galloway (2001);
Gonzalez et al. (2001); Zhang et al. (2006)
p130 + (binding and degradation) b (binding and degradation) Dyson et al. (1992); Helt and Galloway (2001); Zhang et al. (2006)
E2F1 + b Hwang et al. (2002)
E2F6 + + McLaughlin-Drubin et al. (2008)
Cyclin A + Dyson et al. (1992)
Casein kinase II + b Barbosa et al. (1990); Firzlaff et al. (1989)
c-jun + ? Antinore et al. (1996)
MPP2 + ? Luscher-Firzlaff et al. (1999)
SRC-1 + + Baldwin et al. (2006)
α-Tubulin + − Nguyen et al. (2007)
NuMA + + Nguyen and Munger (2009)
S4/26S + ? Berezutskaya and Bagchi (1997)
Cullin 2 + − Huh et al. (2007)
p600 + + Huh et al. (2005)
HDAC + ? Brehm et al. (1999)
HATc + + Bernat et al. (2003); Avvakumov et al. (2003); Huang and McCance (2002)
TBP + + Massimi et al. (1996); Maldonado et al. (2002); Phillips and Vousden (1997)
PP2A + + Pim et al. (2005)
PML + + Bischof et al. (2005)
M2-PK + − Zwerschke et al. (1999)
BRCA-1 + ? Zhang et al. (2005b)
DNMT1 + ? Burgers et al. (2007)
a Binding may be direct or indirect.
b b indicates that the E7 protein binds less well than the related HPV 16 E7 protein.
c Combined data for p300 and pCAF binding.
Table 4
Functions of HPV E7.
Function High-risk HPV E7
(HPV 16, 18, or 31)
Low-risk HPV E7
(HPV 6 or 11)
References
Transformation of permanent rodent cells + − Banks et al. (1990a); Barbosa et al. (1990);
Edmonds and Vousden (1989); Watanabe et al. (1990);
Watanabe et al. (1992)
Cooperation with ras + − Banks et al. (1990a); Chesters et al. (1990);
Firzlaff et al. (1991); Jewers et al. (1992);
Phelps et al. (1992); Storey et al. (1990b)
Immortalization + − Jewers et al. (1992); Melillo et al. (1994)
Transactivation of AdE2 promoter + + Edmonds and Vousden (1989); Firzlaff et al. (1991);
Phelps et al. (1992); Storey et al. (1990b); Watanabe et al. (1990)
Induction of DNA synthesis + + Banks et al. (1990a); Morris et al. (1993); Watanabe et al. (1992)
Bypass of growth arrest + − Demers et al. (1996); Helt and Galloway (2001)
Abrogation of p21CIP1 inhibition + b Funk et al. (1997); Helt et al. (2002); Jones et al. (1997a)
Abrogation of Rb-induced quiescence + ? Brehm et al. (1999); Helt and Galloway (2001)
Episomal maintenance + + Flores et al. (2000); McLaughlin-Drubin et al. (2005);
Oh et al. (2004); Thomas et al. (1999)−
Ampliﬁcation of viral genomes + ? Flores et al. (2000); McLaughlin-Drubin et al. (2005)
Genomic instability — centrosome duplications + − Duensing et al. (2000); Duensing and Munger (2003)
Abrogation of senescence + + (PML-induced senescence) Bischof et al. (2005); DeFilippis et al. (2003);
Psyrri et al. (2004); Wise-Draper et al. (2005)
Activation of the c-fos promoter + − Morosov et al. (1994)
Activation of the p73 promoter + − Brooks et al. (2002)
Activation of AKT + + Menges et al. (2006); Pim et al. (2005)
Abrogation of BRCA1 repression of hTERT + ? Zhang et al. (2005b)
Induction of the telomerase promoter + ? Liu et al. (2008)
Induction of cell DNA synthesis in suprabasal cells + + Cheng et al. (1995); Chien et al. (2000);
Collins et al. (2005); Flores et al. (2000)
Delay of differentiation + + Collins et al. (2005); Flores et al. (2000);
Jones et al. (1997a); Zhang et al. (2006)
Downregulation of miR-203 + ? Melar-New and Laimins (2010)
Upregulation of SIRT1 + ? Allison et al. (2009)
Induction of EZH2 + + Holland et al. (2008)
Upregulation of Nucleophosmin + ? McCloskey et al. (2010)
Upregulation of KDM6A/B + ? McLaughlin-Drubin et al. (2011)
Prolonged G2 + ? Banerjee et al. (2011)
Induction of mIR-16-1 + ? Zheng and Wang (2011)
STAT-1 suppression + − Hong et al. (2011); Thomas et al. (2001)
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regions referred to as conserved region 1 (CR1) and conserved region
2 (CR2) (Phelps et al., 1992; Phelps et al., 1988) (Fig. 2). This conser-
vation allowed the rapid recognition that high-risk HPV E7 binds the
retinoblastoma tumor suppressor protein (Rb) (Fig. 2, Table 3)
(Barbosa et al., 1990; Dyson et al., 1989). Further, adjacent to the Rb
binding site is a casein kinase II recognition sequence, also shared
by the three viruses (Barbosa et al., 1990; Firzlaff et al., 1989). In ad-
dition, E7 shares with adenovirus E1A the ability to transactivate the
adenovirus E2 promoter (Phelps et al., 1988) and to induce cellular
DNA synthesis (Sato et al., 1989) (Table 4). Two other post-
translational modiﬁcations of E7 have been reported. An unknown ki-
nase phosphorylates a site in the C terminus of high-risk HPV E7 dur-
ing S phase (Massimi and Banks, 2000) and PKC, at least in vitro, can
phosphorylate a site in CR1 of low-risk but not high-risk HPV E7
(Armstrong and Roman, 1995).
The intracellular localization of high-risk and low-risk HPV E7s
and whether there are differences in location that might explain func-
tional differences are not completely established. Using tagged HPV
16 E7 and immunoﬂuorescence, the E7 protein was found mainly in
the nucleus (Smith-McCune et al., 1999). By immunoﬂuorescence,
both untagged high-risk and low-risk HPV E7 proteins are mostly nu-
clear but only the low-risk HPV E7 co-localizes with PML in PML on-
cogenic domains (PODs) while the high-risk HPV E7 is distributed
more diffusely (Guccione et al., 2002). In contrast, when analyzed
by subcellular fractionation, high-risk HPV E7 is mostly cytoplasmic
(Nguyen and Munger, 2009; Smotkin and Wettstein, 1987). Consis-
tent with both nuclear and cytoplasmic localization, high-risk HPV
E7 contains both nuclear localization and nuclear export signals
(Knapp et al., 2009); HPV 6 E7 has a putative nuclear export signal
(Barrow-Laing et al., 2010). Both high and low-risk HPV E7s can
alter the intracellular location of cellular proteins, increasing their
presence in the cytoplasm (Baldwin et al., 2006; Barrow-Laing et al.,
2010; Westbrook et al., 2002).
With a few exceptions (see further binding partners in subsequent
sections), the afﬁnity of low-risk HPV E7 for a given target has often
been found to be lower than that of the high-risk HPV E7. Both the af-
ﬁnity of binding of E7 to Rb and the efﬁciency of phosphorylation of
E7 by casein kinase II are lower for low-risk HPVs than for high-risk
HPVs (Barbosa et al., 1990; Gage et al., 1990; Munger et al., 1989b).
Further, low-risk HPV E7 can stimulate DNA synthesis in rodent
cells and in organotypic keratinocyte raft cultures and transactivate
the Ad E2 promoter although perhaps to a lesser extent than high-
risk HPV E7 (Cheng et al., 1995; Watanabe et al., 1992).
Information gained by the use of chimeras or amino acid swaps between
high and low-risk HPV E7
In initial experiments designed to assign regions of E7 responsible
for high-risk HPV E7 activities, chimeras were made of the N-terminal
half of high-risk HPV 16 E7 and the C-terminal half of low-risk HPV 6
E7, and vice versa. The ability of these chimeric proteins to cooperate
with ras to transform primary BRKs and to transactivate the AdE2
promoter was determined (Munger et al., 1991). The results sug-
gested that the C-terminal halves of the proteins were comparable,
that the N-terminal half contained the transforming activity, and
that there was no signiﬁcant difference in the ability of HPV 6 E7
and HPV 16 E7 or the chimeras to transactivate the AdE2 promoter
(Heck et al., 1992; Munger et al., 1991; Takami et al., 1992). When
the N-terminal half was subdivided into three parts, CR1, Rb binding
site, and the CKII phosphorylation site, and all combinations of
high-risk HPV E7 and low-risk HPV E7 were constructed, the Rb bind-
ing site fragment was the sole determinant of the afﬁnity of E7 for Rb
and of cooperation with ras to transform primary rodent cells. Amino
acid swaps revealed that the amino acid N-terminal to the LXCXE Rb
binding motif (aspartate in the case of HPV 16 compared to glycine inthe case of HPV 6) dictated the afﬁnity of E7 for Rb binding and also
the efﬁciency of transformation of rodent cells (Heck et al., 1992;
Sang and Barbosa, 1992). However, this single change did not result
in gain of immortalization function by low-risk HPV E7 (Hu et al.,
1995). These results are consistent with the interpretation that activ-
ities in CR1 are also necessary for immortalization. It is important to
emphasize, however, that the N-terminal region swaps were all in
the context of the HPV 16 E7 C-terminus. As will be described in the
sections below, the C-terminal region is also pertinent to the onco-
genic activity of high-risk HPV E7 and the activities of the C-termini
of low-risk HPV E7 and high-risk HPV E7 are not equivalent.
Mutational analysis of E7 directed at dissecting its functions:
transformation, Ad E2 transactivation, stimulation of DNA synthesis,
and Rb binding
Extensive mutational analysis of the high-risk HPV E7s has
allowed dissection of E7 activities. Experiments conducted with
mutated E7 in rodent cells indicated that the induction of DNA
synthesis and Rb binding can be distinguished from transactivation
and from transformation in some cases but are overlapping in
others (Banks et al., 1990b; Barbosa et al., 1990; Phelps et al.,
1992; Rawls et al., 1990; Storey et al., 1990a; Watanabe et al.,
1990). For example, the Rb binding motif in CR2 is required for
stimulation of DNA synthesis, for transactivation and for the ability
to cooperate with ras in transformation; amino acids 6–10 (PTLHE)
in CR1 are not required for Rb binding or transactivation but are
required for E7 to cooperate with ras in transformation; and an-
other mutation in CR1 is proﬁcient for inducing DNA synthesis
but not for transformation. A high-risk HPV E7 mutated in the
CKII site is fully competent to transactivate the AdE2 promoter
(Firzlaff et al., 1991). However, the role of the CKII site in cooper-
ation with activated ras to transform primary rodent cells is
unclear: in one case, mutating the site results in loss of function;
in another report, there is little effect (Firzlaff et al., 1991; Heck
et al., 1992). In total, the results are consistent with the interpreta-
tion that stimulation of DNA synthesis and transactivation might
be more relevant to E7 functions needed for completion of the
virus life cycle while additional functions are required for the on-
cogenic activity of the high-risk HPV E7.
As noted earlier, the C-terminal half of E7 contains a zinc binding
site, composed of two C-X-X-C motifs (Barbosa et al., 1989; McIntyre
et al., 1993). Early experiments indicated that this region is impor-
tant for protein stability (Watanabe et al., 1990). Thus, interpretation
of mutations requires establishing either the stability of the protein
or its ability to function in other assays. Originally the zinc binding
site of high-risk HPV E7 appeared to be required for dimerization
of E7 and for transformation of rodent cells as well as immortaliza-
tion of keratinocytes (Jewers et al., 1992; McIntyre et al., 1993).
However, recent mutational analysis has shown that dimerization
is not required for E7 to cooperate with ras to transform rodent
cells (Todorovic et al., 2011). The C-terminus in high-risk HPV E7 is
also required to allow bypass of growth arrest (Helt et al., 2002),
and to abrogate Rb-induced quiescence (Brehm et al., 1999; Helt
et al., 2002).
E7 and the retinoblastoma tumor suppressor family, Rb, p107, p130 and
other cell cycle regulators
Inducible expression of E7 in growth arrested cells indicates that
E7 induces cellular DNA synthesis at the G1 to S transition (Banks
et al., 1990a). The implication of E7's binding to the Rb protein be-
came clear when it was shown that this releases the transcription fac-
tor E2F (later to become a family of transcription factors) (Chellappan
et al., 1992). The ability to disrupt this complex requires sequences in
the C-terminus and is greater for high-risk HPV E7 than for low-risk
87A.J. Klingelhutz, A. Roman / Virology 424 (2012) 77–98HPV E7 (Helt and Galloway, 2001; Huang et al., 1993; Patrick et al.,
1994; Wu et al., 1993). This ability, however, is not sufﬁcient to max-
imally stimulate DNA synthesis (Morris et al., 1993). Further, in im-
mortalization assays, addition of E2F1 is sufﬁcient to complement
an E7 mutant deﬁcient in binding Rb, but is not sufﬁcient to comple-
ment an E7 mutated in the N-terminus, indicating that E7-mediated
immortalization requires more than release of E2F1 following binding
and degradation of Rb (Melillo et al., 1994).
High-risk HPV E7 binds the other Rb family members, p107 and
p130, and point mutations within the LXCXE motif show that high-
risk HPV E7 is able to distinguish between Rb family members
(Carlotti and Crawford, 1993; Ciccolini et al., 1994; Davies et al.,
1993). Low-risk HPV E7 binds the Rb family members with lower af-
ﬁnity (Demers et al., 1996; Gage et al., 1990; Munger et al., 1989b).
HPV 16 E7 targets all three Rb family members for degradation;
HPV 6 E7 only targets p130 for degradation (Boyer et al., 1996;
Demers et al., 1994a; Gonzalez et al., 2001; Helt and Galloway,
2001; Jones and Munger, 1997; Zhang et al., 2006). Degradation of
Rb family members requires sequences in CR1 and CR3 in addition
to the LXCXE motif (Giarre et al., 2001; Gonzalez et al., 2001; Helt
and Galloway, 2001; Jones and Munger, 1997; Zhang et al., 2006).
High-risk HPV 16 E7, but not HPV 18 E7, hijacks the cullin 2 E3 ubi-
quitin ligase complex to target Rb for degradation (Huh et al.,
2007). The mechanism(s) of degradation of p130 by high-risk and
low-risk HPV E7 appears to differ: higher levels of cytoplasmic p130
are seen in high-risk HPV E7 expressing cells while a shorter half
life for p130 in the nucleus is seen when low-risk HPV E7 is expressed
(Barrow-Laing et al., 2010). The ability of low-risk HPV E7 to target
p130 for degradation is dependent upon CKII-phosphorylation of E7
(Genovese et al., 2008).
Differences in ability of high-risk and low-risk HPV E7 to transac-
tivate E2F-responsive promoters may relate to which Rb family
member(s) regulates that promoter. In particular, both high-risk
HPV E7 and low-risk HPV E7 transactivate the AdE2 promoter to
the same extent in a cervical carcinoma cell line which is HPV-
negative and contains a mutated Rb (C33A cells), however, in pri-
mary human foreskin keratinocytes, expression of high-risk HPV
E7 results in greater transactivation of the AdE2 promoter than
low-risk HPV E7 (Armstrong and Roman, 1997). In these latter
cells, both low and high-risk HPV E7 transactivate the B-myb pro-
moter, regulated by p107/p130, equally (Armstrong and Roman,
1997). These data suggest that the ability of low-risk HPV E7 to dis-
rupt the interaction of p107/p130 with E2F is equivalent to high-risk
HPV E7, while low-risk HPV E7 is less efﬁcient than high-risk HPV
E7 in disrupting the interaction of Rb with E2F.
The outcome of disruption of Rb family-E2F complexes is the
release of repression of E2F-responsive genes. An ever expanding
number of such genes are recognized, including cyclin A and E,
p21CIP1, DNA polymerase α, PCNA, which serve to drive cells into S
phase and induce cellular DNA synthesis as well as functioning to
turn off the cycle. Interestingly, hTERT also contains an E2F site and
high-risk HPV E7 can enhance expression of E6-mediated hTERT
through this site (Liu et al., 2008). This activity is dependent upon
an intact Rb binding site motif. The high-risk HPV E7s, but not low-
risk E7, transactivate the p73 promoter in HFKs, an activity dependent
upon the Rb binding site (see Table 3) and suggested to be dependent
upon E2F1 (Brooks et al., 2002).
Further, the high-risk HPV E7s bind cyclin A and cdk2 (Dyson et
al., 1992; Tommasino et al., 1993). Similar to binding to Rb family
members, high-risk HPV E7s have a greater afﬁnity for cyclin A than
do low-risk HPV E7s (Ciccolini et al., 1994). High-risk but not low-
risk HPV E7 binds the E2F-cyclin A complex; this binding requires
the Rb binding site but not the CR1 PTLHE sequence (Arroyo et al.,
1993). In a separate series of experiments, both low and high-risk
HPV E7 were found to bind puriﬁed cdk2 and stimulate its kinase ac-
tivity (He et al., 2003).It is interesting to note that while high-risk HPV E7 can bypass
growth arrest mediated by DNA damage or differentiation, low-risk
HPV E7 cannot (Demers et al., 1996). Yet, as noted above, both high
and low-risk HPV E7 can stimulate DNA synthesis although high-
risk HPV E7 is more effective. This is consistent with later observa-
tions that bypass of growth arrest requires both degradation of Rb
and abrogation of p21CIP1, (Helt et al., 2002; Helt and Galloway,
2001). Abrogation of p21CIP1 inhibition requires sequences in the C-
terminus of E7: the zinc binding site mutants are proﬁcient for degra-
dation of all three Rb family members, yet unable to overcome
growth arrest (Helt et al., 2002). Not only does low-risk HPV E7 not
target Rb for degradation, it also is less efﬁcient than high-risk HPV
E7 in abrogating p21CIP1 activity (Funk et al., 1997; Jones et al.,
1997a).
HPV 1 E7: an informative anomaly
While it would be tempting to say that the afﬁnity of E7 for Rb
family members and cyclin A/cdk complexes dictates whether the
protein can activate an E2F-regulated promoter and is oncogenic,
HPV 1 E7 precludes reaching this conclusion. HPV 1 is a Mu-HPV
that is associated with benign skin lesions. HPV 1 E7 binds Rb and cy-
clin A with afﬁnity similar to the high-risk HPVs, yet this protein is
neither a transactivator of the AdE2 promoter nor an oncoprotein
(Ciccolini et al., 1994). Further, unlike either high-risk HPV E7 or
low-risk HPV E7, HPV 1 E7 does not abrogate C/EBP-mediated growth
arrest, an activity dependent upon the CKII site present in the alpha-
HPV E7s but not HPV 1 E7 (Muller et al., 1999) (see next section).
E7 activates other promoters/cis elements and may participate in chro-
matin remodeling through Rb-dependent and Rb-independent activities
In rodent cells, high-risk HPV E7 but not low-risk HPV E7 transac-
tivates the c-fos promoter and does so through the cyclic AMP re-
sponsive element (Morosov et al., 1994). High-risk HPV E7 activates
ATF, Oct 1, MPP2 and AP-I (Antinore et al., 1996; Luscher-Firzlaff
et al., 1999; Wong and Ziff, 1996). Expression of E7 also alters C/
EBPα function. In rodent ﬁbroblasts both high-risk and low-risk
HPV E7 abrogate the growth inhibitory effects of C/EBP (Muller
et al., 1999). This activity requires the CKII site but not the Rb binding
site. Further, high-risk HPV E7 enhances the differentiation promot-
ing activity of C/EBP. The activity of low-risk HPV E7 was not deter-
mined (Muller et al., 1999). High-risk HPV E7s bind E2F1 and
transactivate E2F-responsive promoters more efﬁciently than low-
risk HPV E7s (Hwang et al., 2002). Further, high-risk HPV E7 binds
BRCA1 and blocks its ability to repress hTERT; this activity is depen-
dent upon the C-terminus of E7 (Zhang et al., 2005b). Finally, both
low and high-risk HPV E7s bind TBP and this binding is enhanced
when E7 is phosphorylated by CKII (Massimi et al., 1996; Phillips
and Vousden, 1997). Amino acids within the zinc binding site are re-
quired for binding of E7 to TBP (Massimi et al., 1997) but not for
transactivation of the AdE2 promoter. Massimi et al. suggest that E7
may pull TBP away from a p53 complex, thereby inhibiting p53 trans-
activation activity (Massimi et al., 1997). However, a more recent re-
port indicates that binding to TBP decreases its ability to interact with
DNA (Maldonado et al., 2002). The potential implication of binding of
E7 to TBP on viral replication will be discussed in the viral life cycle
section below.
High-risk HPV E7 can also repress at least one promoter, the E-
cadherin promoter, by binding to and activating DNA methyl trans-
ferase 1, Dnmt-1, (Laurson et al., 2010). This binding is Rb-
independent, requires E7 C-terminal amino acids 84–96 (Burgers
et al., 2007; Laurson et al., 2010). The E-cadherin promoter itself is
not methylated suggesting that Dnmt-1 is affecting the expression
of another gene whose product then represses E-cadherin. The iden-
tity of this other gene(s) is not yet established nor has the region of
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seems to be independent of Rb degradation (Laurson et al., 2010).
High-risk HPV E7 interacts with both histone acetyltransferases
(HAT) and histone deacetylases (HDAC), as well as coactivators
through sequences in CR1, CR2 and the C-terminus (Avvakumov et
al., 2003; Baldwin et al., 2006; Bernat et al., 2003; Brehm et al.,
1999; Huang and McCance, 2002). High-risk HPV E7 upregulates ex-
pression of cdc25a and this activity requires both binding to Rb and
binding to HDAC (Nguyen et al., 2002). Expression of HPV 16 E7 re-
sults in a global increase in the level of acetylation of histones and
speciﬁc increase on E2F-regulated promoters. Increased expression
from these promoters is lost when cells express high-risk HPV E7mu-
tated in either the Rb binding site or the HDAC binding site (located in
the C-terminus (Zhang et al., 2004)). In contrast, increased transcrip-
tion from HIF-1α-responsive promoters is Rb-binding independent
but HDAC-binding dependent (Bodily et al., 2011b). The effect of
low-risk HPV E7 on HATs and HDACs has not been reported. Low-
risk HPV E7 also binds HIF-1α but whether it can displace HDAC
was not established.
High-risk HPV E7 further induces chromatin remodeling by the in-
duction of EZH2, a histone methyl transferase, and of two histone
demethylases (KDM6A and KDM6B) (Holland et al., 2008;
McLaughlin-Drubin et al., 2011). Transcriptional regulation of EZH2
is presumed to be mediated by Rb because an E7 mutant that fails
to bind Rb also fails to induce EZH2. Induction of transcription of
KDM6A and KDM6B, in contrast, is Rb-independent. Interestingly,
this latter activity provides a means by which high-risk HPV E7 can
increase expression of the cell cycle inhibitor, p16INK4A. Whether
these demethylases are also induced by low-risk HPV E7 proteins
has not been reported but EZH2 is induced by low-risk HPV E7. This
shared E7 activity is likely related to the virus life cycle since EZH2
plays a role both in inducing proliferation and in inhibiting apoptosis
(see below).
Cross talk between the Rb and p53 pathways
Although high-risk HPV E6, but not E7, targets p53 for degrada-
tion (see E6 section), E7 does affect p53 expression and function.
High-risk HPV E7 abrogates p53-mediated growth arrest; low-risk
HPV E7 does not (Demers et al., 1994b; Hickman et al., 1994;
Vousden et al., 1993). High-risk HPV E7 increases the steady state
level of p53 (Demers et al., 1994b; Jones et al., 1997b) through an
ARF-independent mechanism (Seavey et al., 1999). In some cell
types and model systems this elevated p53 is transcriptionally ac-
tive: MDM2 and p21CIP1, for example, are induced (Jones and
Munger, 1997; Morozov et al., 1997; Pei et al., 1998; Ruesch and
Laimins, 1997; Seavey et al., 1999; Wang et al., 1996; Zerfass-
Thome et al., 1996). In others, the elevated p53 is not transcription-
ally active and E7 increases the steady state level of p21CIP1 protein
(Eichten et al., 2002; Jones et al., 1999). Notably, high-risk HPV E7
disrupts the interaction of mdm2 with p53, abrogates the growth
inhibitory effect of p21CIP1 and p27KIP1 and targets Rb family mem-
bers (the downstream targets of cyclin-dependent kinase inhibi-
tors) for degradation, releasing E2Fs (Jones and Munger, 1997;
Seavey et al., 1999; Wang et al., 1996; Zerfass-Thome et al.,
1996). The need to inactivate both the p53 and Rb pathways has
become clearer through a set of experiments that showed that
both the ability of E7 to target Rb for degradation and to inhibit
p21CIP1 are required for bypass of growth arrest (Helt et al., 2002;
Helt and Galloway, 2001). Yet, in several model systems, E7 cannot
block p53-mediated apoptosis (Jones et al., 1997b; Stoppler et al.,
1998; Wang et al., 1996). In contrast to high-risk HPV E7, low-
risk HPV E7 is much less efﬁcient at binding p21CIP1 and abrogating
its ability to inhibit cdk2 activity (Funk et al., 1997; Jones et al.,
1997a). As noted earlier, the high-risk HPV E7s transactivate the
p73 promoter in HFKs; a low-risk HPV E7 does not. Thistransactivation is dependent upon the Rb binding site and sug-
gested to be dependent upon E2F1 (Brooks et al., 2002). An isoform
of p73, p73Δ2, inhibits the ability of both p53 and p73 to induce
apoptosis (Fillippovich et al., 2001). It is possible that whether E7
causes apoptosis or not reﬂects differences in the relative abun-
dance of the p73 isoforms.
E7 and apoptosis, senescence, autophagy
It is generally accepted that all viruses have to inhibit apoptosis,
a host response to infection, in order for the virus to have sufﬁcient
time to produce more virus. However, the response of the cell to
the induction of unscheduled S phase entry necessary to this pro-
ductive cycle, may also send host death response signals. While cer-
tain E7 functions send pro-apoptotic signals, these are countered
not only by E6 functions but also by other E7 functions. As noted
in a previous section, E7 can stabilize p53, resulting in some
cases, in an apoptotic response. Further, as noted above, release of
E2F may upregulate p73, another inducer of apoptosis. Both low
and high-risk HPV E7s increase AKT activity that may inhibit the
apoptosis induced when E7 maintains an S phase environment
within the differentiated compartment (Menges et al., 2006; Pim
et al., 2005). High-risk HPV E7 may also inhibit apoptosis by bind-
ing glutathione S-transferase P1 and inhibiting the phosphorylation
of JNK; whether this is also true for low-risk HPV E7 was not exam-
ined (Mileo et al., 2009). Several point mutations within the high-
risk HPV E7 zinc binding site result in loss of binding to GST P1
and loss of the ability of E7 to abrogate UV-induced apoptosis in
HaCat cells (Mileo et al., 2009). Finally, high-risk HPV E7 increases
the level of SIRT1, an NAD-dependent deacetylase, in HFKs.
Knock-down of this deacetylase results in apoptosis of SiHa cells
(Allison et al., 2009).
Expression of high-risk HPV E7 in HeLa cells, after silencing the
endogenous high-risk HPV E6 and E7 genes, results in some cells pro-
liferating, some undergoing senescence and some undergoing apo-
ptosis (DeFilippis et al., 2003). Mutations in CR1 or CR2 of E7, which
cause an inability to inactivate Rb, resulted in greater levels of senes-
cence but neither proliferation above background nor apoptosis
(Psyrri et al., 2004). One negative mediator of senescence that is
upregulated in high-risk HPV E7 but not low-risk HPV E7-
expressing keratinocytes is DEK (Wise-Draper et al., 2005). A positive
mediator of senescence, promyelocytic leukemia protein IV (PML IV)
can, at least in ﬁbroblasts, be bound and its activity inhibited by both
high-risk and low-risk HPV E7. This requires both Rb-dependent and
Rb-independent activities since this activity is lost when high-risk
HPV E7 is mutated in either the Rb binding site or in the C-terminal
half of HPV 16 E7 (Bischof et al., 2005). E7 appears to disrupt the
PML:p53:CBP complex that is responsible for increasing p53-
mediated transcription (Bischof et al., 2005).
Most recently, high-risk HPV E7 has been shown, in the absence of
E6, to induce autophagy in response to growth factor deprivation
(Zhou and Munger, 2009). An activity in the C-terminus of high-risk
HPV E7, not shared with the low-risk HPV E7, is the interaction
with M2 pyruvate kinase, M2-PK. This interaction results in a less ac-
tive form of the enzyme, reducing the cell's requirement for oxygen
and increasing glycolysis (Zwerschke et al., 1999). Combining these
two sets of data, the authors suggest that autophagy may be the cel-
lular response to enhanced proliferation in the absence of appropriate
nutrients or the E7-induced increased requirements for energy (Zhou
and Munger, 2009; Zhou et al., 2009).
Genomic instability: aberrant centrosome duplication, mitotic abnormal-
ities, and bypass of DNA damage checkpoints
In contrast to the shared ability to disrupt the G1/S phase check-
point regulated by Rb family members, high-risk HPV E7 but not
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Some bypass of checkpoints is due to Rb-dependent and other to Rb-
independent activities of E7. Abnormal centrosome duplication is not
dependent upon inactivation of Rb family members (Duensing and
Munger, 2003). Rather centrosome ampliﬁcation may, in part, be
due to binding of E7 to gamma-tubulin and disruption of its interac-
tion with centrosomes (Nguyen et al., 2007). Further, centriole multi-
plication correlates with E7-induced increased expression of Polo-like
kinase 4 (Korzeniewski et al., 2011). High-risk HPV E7 upregulates
several proteins which target claspin, a positive regulator of the mi-
totic checkpoint, for degradation, thereby allowing bypass of this
checkpoint (Spardy et al., 2009). This E7 activity is presumed to be
Rb-dependent because several cellular proteins involved in this deg-
radation are encoded by genes regulated by E2F transcription factors
(Spardy et al., 2009). High-risk HPV E7 can also induce polyploidy
through abrogation of the mitotic spindle checkpoint and/or the post-
mitotic checkpoint (Heilman et al., 2009; Thomas and Laimins, 1998).
Further, activation of the ATM pathway by high-risk HPV E7 may con-
tribute to genomic instability (Moody and Laimins, 2009).
Both low and high-risk HPV E7 is required for the life cycle of the virus
As noted above, HPVs infect the basal cells of the epithelium
through microabrasions. These cells are the site of the non-
productive stage of the viral life cycle where genomes are maintained
at approximately 50 copies per cell. When the cells move off the base-
ment membrane and into the suprabasal compartment, the virus en-
ters the permissive stage of the viral life cycle. Since cells in this
compartment have normally exited the cell cycle, and HPVs cannot
replicate in such cells, the virus has to create an environment consis-
tent with replication of its genome. Interestingly, in some HPV types,
E7 is required for viral maintenance in the basal cell compartment; in
others it is required for viral ampliﬁcation in the differentiated com-
partment (Flores et al., 2000; Oh et al., 2004; Thomas et al., 1999).
The necessity for E7 in the different compartments does not
completely correlate with the risk level of the virus type: E7 is not re-
quired for maintenance of two high-risk genomes, HPV 16 and 18, in
undifferentiated basal cells (Flores et al., 2000; McLaughlin-Drubin et
al., 2005) but is required for the maintenance of another high-risk
HPV, HPV 31, and low-risk HPV 11 (Oh et al., 2004; Thomas et al.,
1999). Regardless, this links the E7 protein to the virus life cycle as
well as to oncogenic transformation.
Mutational analysis identiﬁed amino acids required for episomal
maintenance and further deﬁned differences between high-risk HPV
types. While HPV 16 E7 deleted in CR1 for PTLHE or deleted in the
Rb binding site in the context of the HPV genome could bemaintained
episomally, HPV 31 mutated to encode a low afﬁnity Rb binding site
was greatly compromised with respect to episomal maintenance
(Flores et al., 2000; Thomas et al., 1999). Differences in the require-
ment for functions in the C terminus of E7, required for HDAC bind-
ing, have also recently been reported (Bodily et al., 2011a). Further,
when the HPV 31 genome carrying the Rb binding site mutant was in-
troduced in the context the HPV 16 genome carrying a mutated E6
gene which could neither target p53 for degradation nor be main-
tained episomally, the double mutant was maintained (Park and
Androphy, 2002). The authors comment that this indicates that the
E6 and E7 genes have evolved to balance each other. Interestingly,
this chimeric genome would, at least in two respects (inability to tar-
get p53 for degradation and having a low afﬁnity Rb binding site) be
similar to a low-risk genome.
As noted in an earlier section, E7 binding to TBP decreases its abil-
ity to interact with DNA (Maldonado et al., 2002). For both low and
high-risk HPVs, competition for binding to the viral origin of replica-
tion and the early promoter might determine whether viral DNA syn-
thesis or transcription occurs. The proteins of interest include the viral
replication proteins E1 and E2, the cellular inhibitor of viral transcriptionand replication CCAAT displacement protein, and TBP (Ai et al., 1999;
Maldonado et al., 2002; Narahari et al., 2006; O'Connor et al., 2000).
Thus, it is possible that E7 contributes to maintenance of the viral ge-
nome not only by enhancing S phase entry but also by decreasing the
amount of available TBP. Why this should be important for viral mainte-
nance of some viral genomes but not others is unclear.
Insight into the mechanism by which the high-risk HPV E7 protein
is required for genome ampliﬁcation in the differentiated compart-
ment has recently been provided. E7 binds to and activates the ATM
DNA repair pathway, possibly resulting in activation of caspase 3/7
and cleavage of the viral replication protein E1 which enhances viral
genome ampliﬁcation (Moody et al., 2007; Moody and Laimins,
2009). Binding to ATM requires the LXCXE motif. If indeed ATM acti-
vation is linked to caspase activation, it is reasonable to expect that
low-risk HPV E7 will also bind and activate ATM to enhance viral ge-
nome ampliﬁcation (Moody et al., 2007). However, as noted earlier,
this activation of ATM may contribute to high-risk-induced genomic
instability. Finally, down-regulation of transcription of STAT-1 by
high-risk HPV E7 is also required for viral ampliﬁcation (Hong et al.,
2011). Presumably this activity is not shared by low-risk HPV E7 since
prior microarray data from this laboratory indicated that STAT-1 was,
in fact, slightly elevated (Thomas et al., 2001). However, it is possible
that STAT-1 is not as efﬁciently induced in low risk HPV infections.
The E7 protein is necessary and sufﬁcient for reprogramming the
differentiation compartment to allow virus replication. There are sev-
eral ways to induce differentiation of keratinocytes: growth of conﬂu-
ent monolayers of HFKs in 2 mM calcium, suspension of HFKs in
methylcellulose, and growth of HFKs in organotypic raft cultures.
Early experiments showed that both low-risk and high-risk HPV E7
were sufﬁcient to reprogram the differentiation compartment of the
organotypic rafts to support DNA synthesis and delay differentiation
(Cheng et al., 1995; Chien et al., 2000; Collins et al., 2005; Flores
et al., 2000). More recent studies showed that the ability of high-
risk HPV E7 to induce cell proliferation and delay differentiation
was separable (Collins et al., 2005). The wild-type high-risk HPV
genome and HPV deleted in the E7 CR1 PTLHE sequence could repro-
gram suprabasal HFKs to proliferate but could not delay differentia-
tion. Both activities required the Rb binding site. Thus, while the
induction of unscheduled DNA synthesis (i.e., DNA synthesis in the
suprabasal compartment) required binding to the Rb family, delayed
differentiation also required degradation of family members. Both
low and high-risk HPV E7 can delay differentiation (Jones et al.,
1997a; Zhang et al., 2006). It is important to emphasize that both
low and high-risk HPV E7s can bind Rb, albeit with different afﬁnities,
but the only degradation function they share is to target p130 for deg-
radation (Zhang et al., 2006). Thus degradation of p130 may be criti-
cal for completion of the virus life cycle and degradation of the other
Rb family members may give high-risk HPV E7s their oncogenic po-
tential. As will be described below, upon differentiation, high-risk
HPV E7 decreases the level of miRNA203 that, in turn, increased the
level of ΔNp63, thereby promoting cell proliferation. The regions of
high-risk HPV E7 needed for this activity have not been deﬁned, nor
is it know whether low-risk HPV E7 also decreases miRNA203.
Uncoupling of proliferation and differentiation, a requirement for
completion of the viral life cycle but also for immortalization
There are a variety of pathways whereby E7s ensure a proliferative
state in the differentiated compartment of the epithelium. The ability
to bypass growth arrest, induced by differentiation correlates with
the ability to abrogate p21CIP1 activity (Jones et al., 1997a). Addition-
ally, E7 can abrogate the ability of C/EBP to block proliferation while
not abrogating its ability to induce differentiation (Muller et al.,
1999). As noted above, common to both low and high-risk HPV E7s
is the ability to target the Rb family member p130 for degradation,
suggesting that its degradation may be critical for the viral life cycle
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cent data indicate that reformation of the p130/DREAM complex, in
an HPV-positive cancer cell line, restored growth arrest (Nor Rashid
et al., 2011). Further, both high and low-risk HPV E7 bind to and inac-
tivate E2F6, an Rb-independent repressor of E2F-responsive pro-
moters which might serve to maintain an S-phase-like environment
(McLaughlin-Drubin et al., 2008). And both high and low-risk HPV
E7 can prolong the G2 phase of cells in the differentiated compart-
ment (Banerjee et al., 2011). Recently, a positive role for the CKII
site in increased expression of S phase proteins in the differentiated
compartment has been reported (Bodily et al., 2011a). A critical dif-
ference, in addition to the binding afﬁnity for Rb family members, in
the ability of low-risk versus high-risk E7 to induce unscheduled
DNA synthesis has recently been mapped to conserved lysines pre-
sent in the low-risk E7s only (Genovese et al., 2011). Further, both
high-risk and low-risk HPV E7s bind nuclear mitotic apparatus pro-
tein 1 (NuMA) and delocalize dynein from mitotic spindles. The au-
thors suggest that this might negatively affect the segregation of
daughter cells into one basal and one suprabasal cell (Nguyen and
Munger, 2009). Via AKT activation, high risk E7 upregulates nucleo-
phosmin, a positive regulator of proliferation and negative regulator
of differentiation (McCloskey et al., 2010). Although the authors pre-
viously showed that Rb was required for E7-induced AKT activity
(Menges et al., 2006), knocking down Rb did not result in increased
nucleophosmin. Thus, it is unclear whether the ability to upregulate
nucleophosmin might be shared by low-risk HPV E7.
p600 binds both low-risk and high-risk HPV E7 (Huh et al., 2005).
Silencing of p600 in a cervical carcinoma cell line expressing high-risk
HPV E6 and E7 results in loss of function with respect to growth in
soft agar, a marker for transformation (Huh et al., 2005). However,
the fact that low-risk HPV E7 can also bind p600 would suggest that
this interaction may also be relevant to the virus life cycle.
Regulation of miRNAs by E7
In contrast to E6, there is much more limited information about
the regulation of miRNAs speciﬁcally by E7. Interestingly, high-risk
HPV E7 has been reported to decrease expression of miR-203, a cellu-
lar microRNA that is normally increased in differentiating cells and
downregulates a p53 family member p63 (in particular the ΔNp63
isoform) and cell proliferation (Melar-New and Laimins, 2010). This
E7-mediated downregulation of miR203 appears necessary for robust
ampliﬁcation of viral genomes, at least in part, by creating a
replication-competent cellular environment. In contrast, high-risk
HPV E7 upregulates the tumor suppressive miR16-1 in rafts cultures
(Zheng and Wang, 2011). The implications of this for the viral life
cycle are unclear. One might expect these E7 activities to be shared
with low risk E7; unfortunately, however, there are no comparable
studies with low risk E7.
Summation of activities of E7 related to life cycle versus oncogenicity
Given that both high and low-risk HPV E7s have to create an en-
vironment in the suprabasal compartment conducive to completion
of the virus life cycle and that this involves an uncoupling of cell
proliferation from differentiation, the oncogenic activities of high-
risk HPV E7 can be discerned after separating out the activities
used by low-risk HPV E7 to complete the virus life cycle. It is not
necessary that both use the same tactic, only that the end result is
the same. Further, the issue of whether both high and low-risk
HPV E7 proteins have the same afﬁnity for a cellular protein may
be misleading since the expression of these proteins may be regulat-
ed differently (certainly the case with respect to their transcription)
and afﬁnity can be overcome with quantity. Unfortunately, a num-
ber of activities identiﬁed in high-risk HPVs have yet to be tested
for low-risk HPV E7. However, the compilation of current datasuggests that the key E7 activities pertinent to the virus life cycle
are: 1) binding of Rb, albeit with different afﬁnities to produce an
S-phase like environment; 2) degradation of p130 to delayed differ-
entiation; 3) subtle disruption of p53 activity with respect to inhi-
biting acetylation of p53; and 4) transactivation of a subset of E2F-
responsive genes. On the other hand, key activities pertinent to
the oncogenic activity of E7, particularly given that E6/E7 immortal-
ized HFKs are not tumorigenic, are 1) the ability of high-risk HPV E7
to promote genomic instability through a variety of mechanisms; 2)
degradation of Rb and p107 which may promote certain aspects of
genomic instability; 3) degradation of all three Rb family members
which may result in induction of a wider range of E2F responsive
genes; and (4) a greater number of mechanisms through which ex-
pression of other cellular genes is modiﬁed. A further take-home
message would be that in addition to designating E7 activities as
Rb-dependent or Rb-independent, it is important to make a distinc-
tion between Rb family members. Finally, since some of the muta-
tions in the C-terminus are overlapping but have not been
consistently tested for the full range of E7 functions attributed to
this region, further work is needed to establish which E7 functions
correlate with which E7 binding activities.
The beta-HPV E6 and E7 proteins
In contrast to the high-risk alpha-HPV genomes, in vivo analyses
indicate that the beta-HPV genomes are rarely integrated in the can-
cer cells and the copy number per cell is usually signiﬁcantly below 1
(Feltkamp et al., 2008; Forslund et al., 2007). However, tumors with
higher-copy number of beta-HPV genomes per cell are often observed
in patients who suffer from epidermodysplasia verruciformis (EV), a
rare genetic disease that confers susceptibility to HPV infection
(Orth, 2006). Further, studies with transgenic mice indicate that
HPV 8, regarded along with HPV 5 as a high-risk HPV in EV patients,
can cause non-melanoma skin cancer (Schaper et al., 2005). Because
of the prevalence of multiple beta-PV types in normal skin and in
non-melanoma skin cancers of non-EV patients, the distinction be-
tween high-risk and low-risk beta-HPVs in non-EV patients is not
clear (Caldeira et al., 2003; Dong et al., 2005; Forslund et al., 2007).
These confounders have led to the possibility that, in contrast to the
alpha-PVs, the beta-PVs may play a “hit and run” role in cancer devel-
opment. The activities of beta-HPV E6 and E7 proteins will be brieﬂy
reviewed here.
Cellular transformation studies on the beta-HPVs, implicated in
non-melanoma skin cancer, have been much less extensive than
those conducted on the alpha-HPVs. However, certain transforming
functions of beta-HPV E6 and E7 have been demonstrated. HPV 38
E7 cooperates with HPV 38 E6 to increase the life span of human ﬁ-
broblasts and keratinocytes (Caldeira et al., 2003). Further, HPV 38
E6 and E7 together activate NFκB and protect cells against TNFalpha
and UV-mediated apoptosis (Hussain et al., 2011). In addition, HPV
38 E6 and E7 perturb the interferon pathway, with most of this effect
being mediated through E6 (Cordano et al., 2008). HPV 38 E6 has
been demonstrated to disrupt p53 signaling through its interaction
with deltaNp73 (Accardi et al., 2006) and with the p300/CBP complex
(Muench et al., 2010). HPV 38 E7, like high-risk alpha HPV E7, binds
to and targets Rb for degradation, abrogates p21CIP1-mediated growth
arrest, transforms rodent cells and overcomes ras-induced senes-
cence (Caldeira et al., 2003). In contrast, the E7 protein of HPV 20,
like low-risk alpha HPV E7, binds Rb with lower afﬁnity and neither
targets it for degradation nor transforms rodent cells.
The E6 and E7 proteins of HPVs 5 and 8, which are found in squa-
mous cell carcinomas of EV and immunosuppressed patients, and
therefore might be designated high-risk based on epidemiology,
also have transforming properties. For example, E6s from HPV 5 and
8 activate telomerase (Bedard et al., 2008), a function that is associat-
ed with high-risk alpha-PVs. HPV 5 and 8 E6s also degrade Bak and
91A.J. Klingelhutz, A. Roman / Virology 424 (2012) 77–98protect keratinocytes from UVB irradiation (Underbrink et al., 2008).
While HPV 5 and 8 E6s are not thought to bind with high afﬁnity to
p53, transcriptional regulation by p53 may be abrogated by other
mechanisms. In this regard, HPV 8 E6 can interact with TIP60 which,
as discussed for high-risk HPV E6, is involved in modifying p53
through acetylation (Jha et al., 2010). In addition, both HPV 5 and
HPV 8 E6s interact with and promote the degradation of p300
(Howie et al., 2011). E7s from HPV 5 and 8 bind Rb with lower afﬁnity
than the high-risk alpha-E7 (e.g., HPV 16 E7), even though each con-
tains what would, based on the alpha-E7s, be considered a high afﬁn-
ity Rb binding site (DLXCXE). Both HPV 5 and HPV 8 E7 cooperate
with ras to transform primary rodent cells, albeit less efﬁciently
than HPV 16 E7 (Yamashita et al., 1993). Further, HPV 8 E7 fails to
morphologically transform rodent cells, is a poor transactivator of the
AdE2 promoter, and fails to immortalize primary human keratinocytes
(Schmitt et al., 1994). YetHPV 8 E7 can alter the proliferation and differ-
entiation program of primary adult epidermal cells grown in organoty-
pic raft cultures and even invade the dermis of these cultures (Akgul et
al., 2005).Most recently, HPV 38 E7 has been shown tohave amore pro-
found effect than HPV 5 and 8 E7 on the differentiation of organotypic
raft cultures, including decreasing expression of the differentiation
marker keratin 10 and increasing the percentage of cells replicating
their DNA. Yet even for HPV 38 E7, these proliferating cells are not
throughout the differentiated layers as they are with the high-risk
alpha-HPV E7. In contrast, HPV 5 and 8 E7-expressing cells in the differ-
entiated layers, like the alpha-HPV E7 expressing cells, express both cy-
clin E and p16INK4a (Westphal et al., 2009). HPV 20 E7 expression results
in raft cultures that share with HPV 8 E7 histological appearance, kera-
tin 10 expression and the location of cells replicating their DNA.The alpha HPV E5 proteins
High-risk HPV E5s are considered minor oncogenes based on their
absence in carcinomas in which the HPV genome is integrated
(Schwarz et al., 1985; Yee et al., 1985). However, episomal copies of
the HPV genome are sometimes seen in carcinomas and the transgenic
mouse model has revealed the oncogenic potential of E5 in both the
skin and cervix, the latter in conjunction with estrogen treatment
(Genther Williams et al., 2005; Maufort et al., 2010; Maufort et al.,
2007). Hence a brief summary of HPV E5 in vitro activity follows.
High-risk HPV E5 can induce anchorage independent growth of
rodent cells and cooperate with E7 to stimulate proliferation and ex-
tend the life of primary rodent cells; these activities are enhanced in
the presence of EGF (Bouvard et al., 1994; Leechanachai et al., 1992;
Valle and Banks, 1995). Most biologically relevant, high-risk HPV E5
can stimulate primary human keratinocytes to proliferate and can en-
hance the efﬁciency of immortalization of keratinocytes by E6 and E7
(Stoppler et al., 1996; Straight et al., 1993).
High-risk HPV E5 binds the 16 kDa component of the vacuolar
ATPase, decreases the acidity of endosomes, decreases trafﬁcking
through the endocytic pathway and increases ligand-dependent sig-
naling through the EGF receptor (Conrad et al., 1993; Hwang et al.,
1995; Straight et al., 1995; Thomsen et al., 2000). While this latter
may be due to the decreased degradation of the EGFR in the endosomes
or to decreased trafﬁcking through the endosome pathway, it may also
be due to E5-mediated disruption of the interaction of c-Cbl, an ubiqui-
tin ligase, with the EGFR (Straight et al., 1995; Thomsen et al., 2000;
Zhang et al., 2005a). Alternatively, the increased signaling may be due
to E5-mediated upregulation of surface gangliosides (Suprynowicz et
al., 2008). These results now appear to be clariﬁed by the recent devel-
opment of new reagents allowing a speciﬁc analysis of endogenous
16 kDa protein, the pH of early endosomes containing EGF, endocytic
trafﬁcking and endosome fusion. High-risk HPV E5 enhances EGF sig-
naling by inhibiting the fusion of EGF-containing early endosomes
with acidic vesicles (Suprynowicz et al., 2010).As with the other high-risk alpha-HPV oncogenes, high-risk HPV
E5 has recently been reported to alter cellular gene expression by reg-
ulating cellular miRNAs. Notably, like high-risk HPV 16 E7, high-risk
HPV E5 down regulates miR-203 (Greco et al., 2011).
E5 activities pertinent to the life cycle of the virus can be gleaned
from three types of experiments: 1) activities of low-risk HPV E5, 2)
the effect of mutated high-risk HPV E5 in the context of the intact ge-
nome on the viral life cycle, and 3) the ability of both low- and high-
risk HPV E5 to contribute to a morphological change typical of HPV-
infected epithelium. Limited experiments with low-risk HPV E5
have shown that it too can induce anchorage independent growth
of rodent cells, co-operate with high-risk HPV E7 to stimulate colony
formation of primary rodent cell, and bind the 16 kDa component of
the vacuolar ATPase (Chen and Mounts, 1990; Conrad et al., 1993;
Valle and Banks, 1995). Life cycle experiments conducted with high-
risk HPV 16 or HPV 31 genomes indicate that E5 does not play a
role in viral maintenance in the non-productive stage of the viral
life cycle (Fehrmann et al., 2003; Genther et al., 2003). In contrast,
E5 does play a role in optimizing the differentiated environment for
completion of the viral life cycle, although knocking out E5 in the con-
text of the HPV 31 genome has more profound effects than when the
experiment is conducted in the context of the HPV 16 genome
(Fehrmann et al., 2003; Genther et al., 2003). For both high-risk
HPV E5s, binding of E5 to B cell receptor-associated protein 31
(Bap31) correlates with the ability of an E5-proﬁcient HPV genome
to amplify its viral genomes (Regan and Laimins, 2008). Finally,
when expressed in primary cervical or foreskin epithelial cells, both
low- and high-risk HPV E5, in conjunction with either low- or high-
risk HPV E6, induce the formation of koilocytes, a cellular manifesta-
tion in the differentiated epithelium characteristic of HPV infection
(Krawczyk et al., 2008).
In sum, both in vitro and in vivo data indicate that E5 has onco-
genic activity. However, the paucity of data with low-risk HPV E5
and the relatively early stage of understanding of the role of HPV E5
in the viral life cycle preclude deﬁnitive identiﬁcation of the HPV E5
oncoprotein-speciﬁc activities. Further, it is interesting to note that
the beta-HPVs do not encode an E5 protein.
Final comments
This review has taken the position that a comparison of activities
of low and high-risk HPVs will allow the identiﬁcation of common ac-
tivities, presumably needed for the viral life cycle, and additional ac-
tivities of high-risk HPVs, presumably essential for transformation/
immortalization. However, it should be acknowledged that another
review has suggested that there may be a fundamental difference in
the cells infected within the basal layer: with high-risk HPVs infecting
stem-like cells where the genome persists and eventually leads to
malignancy and low-risk HPVs infecting transient amplifying cells
giving rise to virus factories in hyperplastic cells. This hypothesis sug-
gests that the replication cycles of the two groups of viruses are quite
different and therefore one can't use low-risk HPV activities to sort
out life cycle events from transformation/immortalization events
(Munger et al., 2004). Later experiments, however, indicate that
both low and high-risk HPV E7s may have the ability to alter the seg-
regation of daughter basal cells, resulting in delayed differentiation
and maintenance of viral genomes (Nguyen and Munger, 2009).
This shared activity plus others discussed in this review suggest that
there is a signiﬁcant overlap in the pathways altered by low and
high-risk HPV E7 validating the comparative approach. Finally, carci-
nomas arise in the transformation zone of the cervix where the co-
lumnar and squamous epithelium meet. It has been postulated that
the intracellular environment of the basal cells in this region, or the
reserve cells which give rise to these basal cells, may somehow limit
completion of the productive life cycle (Doorbar, 2006). Why this
would be more true for high-risk than low-risk HPVs is not clear.
92 A.J. Klingelhutz, A. Roman / Virology 424 (2012) 77–98However, if the productive life cycle cannot be completed, transfor-
mation might be favored, consistent with the polyomavirus literature
cited in the Introduction. Finally, one should also bear in mind that
most experiments are conducted using the reductionist approach
where, for example, the activities of E6 and E7 alone or together are
studied. In a primary infection, these genes would be expressed in the
context of the intact genome where other PV replication proteins, for
example E1 and E2, might tip the balance with respect to the outcome
of infection.
The limited activities of the low-risk PVs, e.g., targeting neither Rb
nor p53 for degradation, may have allowed these PVs to send fewer
distress signals and thereby to better coexist with their host cell. In
contrast, the high-risk viruses, by targeting all Rb family members
for degradation have raised more distress signals, necessitating
more activities, e.g., degradation of p53, to counter the normal host
cell response. The more limited interaction with p53, blocking its
acetylation by p300, and with the Rb family members, targeting
only p130 for degradation and perhaps activating only a subset of
E2F-responsive promoters, for example, appear to be sufﬁcient for
the HPVs to complete their life cycle.
An analysis of the activities of oncoproteins encoded by different
PVs indicates that they have evolved such that the relative oncogenic-
ity of E5, E6 and E7 varies depending upon the PV type. This may re-
ﬂect the balance of activities of proteins within a particular PV type as
well as the particular squamous epithelium they infect. Further, an
analysis of PV functions indicates that when the expression or func-
tion of a given cellular protein must be altered, PVs use overlapping
or redundant approaches to succeed in this endeavor. As examples,
both E6 and E7 alter hTERT expression; and high-risk HPV E6 alters
p53 function both by targeting it for degradation and by inhibiting
its activation.
Finally, while the number of cellular binding partners of high-risk
PV oncoproteins is ever increasing, determining whether these bind-
ing partners also bind low-risk PV proteins continues to be very lim-
ited. Expanding this comparison will enhance the interpretation of
the importance of these different interactions to cellular transforma-
tion versus viral life cycle. Further, given that a particular region of a
PV protein is required for binding to multiple cellular proteins
(Fig. 1 and Fig. 2), it is imperative that not only the ability of low-
risk PV proteins to bind be determined but also that the signiﬁcance
of any particular cellular protein to PV function be established by si-
lencing that cellular protein.
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